US20200271657A1 - Articles and methods directed to personalized therapy of cancer - Google Patents

Articles and methods directed to personalized therapy of cancer Download PDF

Info

Publication number
US20200271657A1
US20200271657A1 US16/753,635 US201816753635A US2020271657A1 US 20200271657 A1 US20200271657 A1 US 20200271657A1 US 201816753635 A US201816753635 A US 201816753635A US 2020271657 A1 US2020271657 A1 US 2020271657A1
Authority
US
United States
Prior art keywords
cell receptor
cell
car
cells
unique
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/753,635
Other languages
English (en)
Inventor
Alexey Vyacheslavovich Stepanov
Dmitry Dmitrievich Genkin
Richard A. Lerner
Alexey Anatolievich Belogurov
Alexander Gabibovich GABIBOV
Jia Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hesperix SA
Scripps Research Institute
Original Assignee
Bioorganic Chemistry Russian Academy Of Sciences
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2017134483A external-priority patent/RU2017134483A/ru
Priority claimed from RU2018112009A external-priority patent/RU2018112009A/ru
Priority claimed from RU2018134321A external-priority patent/RU2018134321A/ru
Application filed by Bioorganic Chemistry Russian Academy Of Sciences, Scripps Research Institute filed Critical Bioorganic Chemistry Russian Academy Of Sciences
Assigned to THE SCRIPPS RESEARCH INSTITUTE reassignment THE SCRIPPS RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: XIE, Jia
Assigned to THE SCRIPPS RESEARCH INSTITUTE reassignment THE SCRIPPS RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OPKO PHARMACEUTICALS, LLC
Assigned to SHEMYAKIN-OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY, RUSSIAN ACADEMY OF SCIENCES reassignment SHEMYAKIN-OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY, RUSSIAN ACADEMY OF SCIENCES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BELOGUROV, ALEXEY ANATOLIEVICH, GABIBOV, Alexander Gabibovich, STEPANOV, ALEXEY VYACHESLAVOVICH
Assigned to PJSC PHARMSYNTHEZ reassignment PJSC PHARMSYNTHEZ ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GENKIN, DMITRY DMITRIEVICH
Assigned to OPKO PHARMACEUTICALS, LLC reassignment OPKO PHARMACEUTICALS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LERNER, RICHARD A
Assigned to Hesperix SA reassignment Hesperix SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BELOGUROV, ALEXEY ANATOLIEVICH, GABIBOV, Alexander Gabibovich, SHEMYAKIN-OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY, RUSSIAN ACADEMY OF SCIENCES, STEPANOV, ALEXEY VYACHESLAVOVICH, GENKIN, DMITRY DMITRIEVICH, PJSC PHARMSYNTHEZ
Publication of US20200271657A1 publication Critical patent/US20200271657A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • Lymphoma is a cancer in the lymphatic cells of the immune system.
  • lymphomas present as a solid tumor of lymphoid cells. These malignant cells often originate in lymph nodes, presenting as an enlargement of the node, i.e., a tumor. It can also affect other organs in which case it is referred to as extranodal lymphoma. Extranodal sites include the skin, brain, bowels and bone. Lymphomas are closely related to lymphoid leukemias, which also originate in lymphocytes but typically involve only circulating blood and the bone marrow and do not usually form static tumors (Parham, P. The immune system. New York: Garland Science. p. 414, 2005). Treatment involves chemotherapy and in some cases radiotherapy and/or bone marrow transplantation, and can be curable depending on the histology, type, and stage of the disease. More advanced cases of lymphoma are resistant and, accordingly, novel treatment approaches are needed.
  • the disclosure provides methods for treatment of B cell malignancies using personalized medicine. More particularly, the methods provide for isolating a B cell receptor from a B cell malignancy in a subject, identifying a ligand for the B cell receptor, and then treating the subject with the B cell receptor ligand coupled to a therapeutic agent, e.g., a CART cell in which the B cell receptor ligand comprises the antigen binding domain.
  • a therapeutic agent e.g., a CART cell in which the B cell receptor ligand comprises the antigen binding domain.
  • the methods of the disclosure use an autocrine-based format to identify B cell receptor ligands specific to a tumor. Once a B cell receptor ligand is identified, a patient can be treated with the ligand attached to a therapeutic agent. The whole process, from diagnosis to treatment can be completed in a short period of time, e.g., within several weeks.
  • B cell receptor ligands may be identified by co-expressing a B cell receptor from a tumor and a chimeric antigen receptor (CAR) in a T cell, where the extracellular domain of the CAR comprises a peptide from a library.
  • CAR chimeric antigen receptor
  • Activation of the T cell by the CAR indicates that the extracellular domain of the CAR has bound the B cell receptor and the peptide from the peptide library is a B cell receptor ligand.
  • contemplated herein is the use of phage display for identification of the B cell receptor ligand.
  • the disclosure also provides methods for treatment of cancer by administering CAR-expressing T-cells, wherein the CAR comprises an antigen binding domain that specifically binds a cancer-specific antigen in a cancer-specific manner, e.g., a CAR with an antigen binding domain comprising a B cell receptor ligand as is described herein; and a vaccine comprising a polypeptide or a nucleic acid expressing the same cancer-specific antigen, or a cancer-specific fragment thereof, e.g., a B cell receptor or fragment thereof.
  • a CAR specific for a cancer antigen and that same antigen are administered to a subject, the two have a synergistic effect on a reduction in tumor volume.
  • kits for treating lymphoma in a subject comprise:
  • the putative unique B cell receptor ligand comprises a peptide, a cyclopeptide, a peptoid, a cyclopeptoid, a polysaccharide, a lipid, or a small molecule.
  • the unique B cell receptor and the putative unique B cell receptor ligand are co-expressed in T cells.
  • the cell comprises a CAR comprising the putative unique B cell receptor ligand.
  • the unique B cell receptor is contacted with a putative unique B cell receptor ligand from a library by phage display.
  • the library comprises a library of putative B cell receptor ligands linked to a phage.
  • the unique B cell receptor is attached to a solid support.
  • contacting unique B cell receptor with a putative unique B cell receptor ligand from a library comprises panning the unique B cell receptor attached to a solid support with the library of putative B cell receptor ligands linked to a phage for one or more rounds. In some embodiments, each round of the panning includes negative selection.
  • said detection method comprises identifying activation of the T cell.
  • kits for treating lymphoma in a subject comprise:
  • the unique B cell receptor and the putative unique B cell receptor ligand are co-expressed in T cells.
  • the T cell comprises a CAR comprising the putative unique B cell receptor ligand.
  • said detection method comprises identifying activation of the T cell.
  • the subject is administered the B cell receptor, or a fragment thereof, concomitantly with the therapeutic agent.
  • provided herein are methods of identifying a B cell receptor ligand.
  • the methods comprise:
  • each CAR within the library comprises a distinct putative B cell receptor ligand domain
  • the putative B cell receptor ligand domain of a CAR from the library of CARs comprises a ligand of the B cell receptor if a T cell expressing the B cell receptor and the CAR is activated;
  • the B cell receptor is from a cancer cell.
  • the cancer cell is a lymphoma cell.
  • the lymphoma cell is obtained from a tumor from a patient
  • the methods further comprise treating a subject having lymphoma with the B cell receptor ligand wherein the B cell receptor is expressed in a tumor from the subject; and the B cell receptor ligand coupled to a therapeutic agent.
  • the subject is administered the B cell receptor, or a fragment thereof, concomitantly with the therapeutic agent.
  • kits for treating lymphoma.
  • the methods comprise:
  • the B cell receptor ligand comprises a putative B cell receptor ligand domain
  • a CAR comprising the putative B cell receptor ligand domain activates a T cell when co-expressed with the B cell receptor of the lymphoma cells.
  • kits for treating lymphoma in a subject comprise:
  • each CAR within the library comprises a distinct putative B cell receptor ligand domain
  • identifying a B cell receptor ligand by identifying an activated T cell, wherein the putative B cell receptor ligand domain of the CAR from the library of CARs comprises a ligand of the unique B cell receptor if the T cell expressing the B cell receptor and the CAR is activated;
  • the methods further comprise preparing the B cell receptor ligand coupled to a therapeutic agent.
  • the T cell is activated by autocrine-based activation of the CAR.
  • identifying a B cell receptor ligand further comprises isolating the nucleic acid molecule encoding the CAR from the activated T cell; and sequencing the putative B cell receptor ligand domain of the nucleic acid molecule encoding the CAR from the activated T cell.
  • the subject is administered the B cell receptor, or a fragment thereof, concomitantly with the therapeutic agent.
  • lymphoma in another aspect, provided herein are methods of treating lymphoma in a subject comprising:
  • identifying said unique B cell receptor ligand by a detection method wherein a putative unique B cell receptor ligand is a unique B cell receptor ligand if it interacts with the unique B cell receptor;
  • the unique B cell receptor and a putative unique B cell receptor ligand are co-expressed in T cells.
  • the cell comprises a CAR comprising the putative unique B cell receptor ligand.
  • said detection method comprises identifying activation of the T cell.
  • the subject is administered the B cell receptor, or a fragment thereof, concomitantly with the therapeutic agent.
  • kits for treating lymphoma in a subject comprising: administering to the subject a therapeutically effective amount of a CART cell expressing a first CAR, wherein:
  • the first CAR comprises an antigen binding domain that comprises a polypeptide from a cyclopeptide library that binds a unique B cell receptor expressed in lymphoma cells of the subject,
  • the first CAR has greater specificity and/or activity than a control.
  • control comprises a CART cell.
  • the antigen binding domain of the CAR expressed by the CART cell binds a ligand other than a B-cell receptor. In some embodiments, the antigen binding domain binds CD-19.
  • the first CAR and the second CAR are the same CAR. In some embodiments, the first CAR and the second CAR are different CARs.
  • activity comprises cytotoxicity towards cells expressing the unique B cell receptor relative to a control.
  • cytotoxicity of the CART towards cells expressing the unique B cell receptor is 0%-10% greater than the control, as measured by % lysis, at an effector:target ratio of 1:1-10:1.
  • cytotoxicity of the CART towards cells expressing the unique B cell receptor is at least 10% greater than the control, as measured by % lysis, at an effector:target ratio of 10:1 or greater.
  • control comprises a CAR comprising an antigen binding domain that binds a ligand other than the B-cell receptor expressed on the cells expressing the unique B cell receptor.
  • specificity comprises cytotoxicity towards cells that do not express the unique B cell receptor.
  • cytotoxicity of the CART towards cells that do not express the unique B cell receptor is less than 10%, as measured by % lysis.
  • cytotoxicity of the CART towards cells that do not express the unique B cell receptor is 0-10% less than the cytotoxicity of a control that binds a ligand expressed on the cells at an effector:target ratio of less than 10:1.
  • cytotoxicity of the CART towards cells that do not express the unique B cell receptor is at least 15% less than the cytotoxicity of a control that binds a ligand expressed on the cells at an effector:target ratio of 10:1 or greater.
  • the subject is administered the B cell receptor, or a fragment thereof, concomitantly with the therapeutic agent.
  • kits for treating lymphoma in subject population comprising:
  • the first CAR comprises an antigen binding domain that comprises a polypeptide from a cyclopeptide library that binds a unique B cell receptor expressed in lymphoma cells of each subject,
  • the first CAR has greater specificity and/or activity than a control.
  • control comprises a CART cell.
  • the antigen binding domain of the CAR expressed by the CART cell binds a ligand other than a B-cell receptor. In some embodiments, the antigen binding domain binds CD-19.
  • the first CAR and the second CAR are the same CAR. In some embodiments, the first CAR and the second CAR are different CARs.
  • activity comprises cytotoxicity towards cells expressing the unique B cell receptor relative to a control.
  • cytotoxicity of the CART towards cells expressing the unique B cell receptor is 0%-10% greater than the control, as measured by % lysis, at an effector:target ratio of 1:1-10:1.
  • cytotoxicity of the CART towards cells expressing the unique B cell receptor is at least 10% greater than the control, as measured by % lysis, at an effector:target ratio of 10:1 or greater.
  • control comprises a CAR comprising an antigen binding domain that binds a ligand other than the B-cell receptor expressed on the cells expressing the unique B cell receptor.
  • specificity comprises cytotoxicity towards cells that do not express the unique B cell receptor.
  • cytotoxicity of the CART towards cells that do not express the unique B cell receptor is less than 10%, as measured by % lysis.
  • cytotoxicity of the CART towards cells that do not express the unique B cell receptor is 0-10% less than the cytotoxicity of a control that binds a ligand expressed on the cells at an effector:target ratio of less than 10:1.
  • cytotoxicity of the CART towards cells that do not express the unique B cell receptor is at least 15% less than the cytotoxicity of a control that binds a ligand expressed on the cells at an effector:target ratio of 10:1 or greater.
  • a personalized antibody binding ligand specific for a B cell lymphoma e.g., a B cell receptor ligand, comprising:
  • each CAR within the library comprises a distinct putative B cell receptor ligand domain
  • the putative B cell receptor ligand domain of a CAR from the library of CARs comprises a ligand of the B cell receptor if a T cell expressing the B cell receptor and the CAR is activated;
  • the B cell receptor ligand is identified within 4 weeks, within 3 weeks, within 2 weeks, or within 1 week. In some embodiments, the B cell receptor ligand is identified within 3 weeks.
  • the B cell lymphoma cell is obtained from a tumor from a patient.
  • the putative B cell receptor ligand domain comprises a polypeptide of 30 amino acids or less. In some embodiments, the putative B cell receptor ligand domain comprises a polypeptide from a cyclopeptide library. In some embodiments, the putative B cell receptor ligand domain further comprises an Fc region.
  • T cell activation is measured by an increase in expression of CD69 or CD25. In some embodiments, T cell activation is measured by an increase in expression of a fluorescent protein reporter gene under the control of Jun, NF- ⁇ B and/or Rel.
  • the methods further comprise treating a subject having lymphoma with the B cell receptor ligand, wherein the B cell receptor ligand coupled to a therapeutic agent.
  • CAR chimeric antigen receptor
  • a putative B cell receptor ligand domain that comprises a polypeptide from a cyclopeptide library
  • the CAR activates a T cell when co-expressed with a B cell receptor, wherein a B cell receptor ligand of the B cell receptor comprises the putative B cell receptor ligand domain.
  • the B cell receptor ligand comprises the amino acid sequence of any of SEQ ID NOs: 1-3.
  • lymphoma in another aspect, provided herein is a method of treating lymphoma in a subject comprising:
  • phage display library comprises a library of putative unique B cell receptor ligands linked to phages
  • the putative unique B cell receptor ligand comprises a peptide, a cyclopeptide, a peptoid, a cyclopeptoid, a polysaccharide, a lipid, or a small molecule.
  • the unique B cell receptor is attached to a solid support.
  • contacting unique B cell receptor with a putative unique B cell receptor ligand from a library comprises panning the unique B cell receptor attached to a solid support with the library of putative B cell receptor ligands linked to a phage for one or more rounds. In some embodiments, each round of the panning includes negative selection.
  • the subject is determined to have lymphoma.
  • the subject is determined to have one or more single-nucleotide polymorphisms (SNPs) associated with lymphoma.
  • SNPs single-nucleotide polymorphisms
  • identifying a unique B cell receptor comprises:
  • identifying a unique B cell receptor comprises cloning and sequencing circulating cell free DNA.
  • the method is performed in 3 weeks or less.
  • the therapeutic agent comprises a radioactive isotope.
  • the B cell receptor ligand coupled to a therapeutic agent comprises a therapeutic CAR.
  • the therapeutic agent comprises a chemotherapy.
  • the therapeutic agent comprises an immunotherapy.
  • a method of treating cancer in a subject comprises concomitantly administering: CAR-expressing T-cells, wherein the CAR comprises an antigen binding domain that specifically binds a cancer-specific antigen in a cancer-specific manner; and a vaccine comprising a polypeptide or a nucleic acid expressing the cancer-specific antigen, or a cancer-specific fragment thereof.
  • the cancer-specific antigen is a B-cell receptor. In some embodiments, the cancer is a lymphoma. In some embodiments, the polypeptide or nucleic acid comprises a heavy or light chain variable region, or fragment thereof.
  • the cancer-specific antigen is expressed in the cancer and comprises a somatic mutation.
  • the non-cancerous cells of the subject do not have the somatic mutation.
  • the mutation is a point mutation, a splice-site mutation, a frameshift mutation, a read-through mutation, or a gene-fusion mutation.
  • the somatic mutation comprises a mutation in EGFRvIII, PSCA, BCMA, CD30, CEA, CD22, L1CAM, ROR1, ErbB, CD123, IL13R ⁇ 2, Mesothelin, FR ⁇ , VEGFR, c-Met, 5T4, CD44v6, B7-H4, CD133, CD138, CD33, CD28, GPC3, EphA2, CD19, ACVR2B, anaplastic lymphoma kinase (ALK), MYCN, BCR, HER2, NY-ESO1, MUC1, or MUC16.
  • the cancer comprises a tumor.
  • the polypeptide or nucleic acid comprises the somatic mutation.
  • the concomitant administration occurs at least two times, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, or at least ten times in the subject.
  • the CAR-expressing T-cells are administered before the vaccine. In some embodiments, the CAR-expressing T-cells are administered after the vaccine.
  • the method further comprises identifying the cancer-specific antigen in the subject.
  • identifying the cancer-specific antigen comprises: (i) obtaining cancerous cells from a subject; (ii) extracting DNA from the cells; and (iii) sequencing the DNA.
  • identifying the cancer-specific antigen further comprises comparing the DNA sequence obtained from the cancerous cells to a DNA sequence of the same gene obtained from non-cancerous cells.
  • the DNA is isolated from tumor cells.
  • the cancer-specific antigen comprises isolating and sequencing circulating cell free DNA of the subject.
  • identifying the cancer-specific antigen comprises: (i) obtaining cancerous cells from a subject; (ii) extracting RNA from the cells; (iii) synthesizing cDNA from the extracted RNA; and (iv) sequencing the cDNA. In some embodiments, identifying the cancer-specific antigen further comprises comparing the cDNA sequence obtained from the cancerous cells to a cDNA sequence of the same gene obtained from non-cancerous cells.
  • the vaccine comprises two or more polypeptides having overlapping sequences, each expressing a fragment of the cancer-specific antigen.
  • the method further comprises providing CAR-expressing T-cells by: (i) identifying an antigen binding domain that specifically binds the cancer-specific antigen in a cancer-specific manner; and (ii) expressing a CAR comprising the antigen binding domain in T-cells.
  • the polypeptide is conjugated to KLH.
  • the vaccine is administered by intravenous, intraperitoneal, transmucosal, oral, subcutaneous, pulmonary, intranasal, intradermal or intramuscular administration. In some embodiments the vaccine is administered intratumorally.
  • the CAR-expressing T-cells are administered by intravenous administration.
  • the method further comprises administering a TLR9 agonist.
  • the cancer-specific antigen is OX40.
  • composition for treating cancer in a subject comprising: CAR-expressing T-cells, wherein the CAR comprises an antigen binding domain that specifically binds a cancer-specific antigen in a cancer-specific manner; and a polypeptide or a nucleic acid expressing the cancer-specific antigen, or a cancer-specific fragment thereof.
  • the cancer-specific antigen is a B-cell receptor.
  • the polypeptide or nucleic acid comprises a heavy or light chain variable region, or fragment thereof.
  • the cancer-specific antigen is expressed in the cancer and comprises a somatic mutation.
  • the non-cancerous cells of the subject do not have the somatic mutation.
  • the mutation is a point mutation, a splice-site mutation, a frameshift mutation, a read-through mutation, or a gene-fusion mutation.
  • the somatic mutation comprises a mutation in EGFRvIII, PSCA, BCMA, CD30, CEA, CD22, L1CAM, ROR1, ErbB, CD123, IL13R ⁇ 2, Mesothelin, FR ⁇ , VEGFR, c-Met, 5T4, CD44v6, B7-H4, CD133, CD138, CD33, CD28, GPC3, EphA2, CD19, ACVR2B, anaplastic lymphoma kinase (ALK), MYCN, BCR, HER2, NY-ESO1, MUC1, or MUC16.
  • the polypeptide or nucleic acid comprises the somatic mutation.
  • the vaccine comprises two or more polypeptides having overlapping sequences, each expressing a fragment of the cancer-specific antigen.
  • the polypeptide is conjugated to KLH.
  • the method further comprises administering a TLR9 agonist.
  • the cancer-specific antigen is OX40.
  • the CAR e.g., a CAR described herein, comprises a transmembrane domain.
  • the transmembrane domain comprises alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and/or CD154.
  • the CAR e.g., a CAR described herein, comprises an intracellular region.
  • the intracellular region comprises a MHC class I molecule, a TNF receptor protein, an Immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocytic activation molecule (SLAM protein), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD25/CD18), 4-29B (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R
  • MHC class I molecule
  • the CAR e.g., a CAR described herein, comprises a hinge domain.
  • the therapeutic agent comprises a radioactive isotope.
  • the B cell receptor ligand coupled to a therapeutic agent comprises a therapeutic CAR.
  • the therapeutic agent comprises a chemotherapy.
  • the therapeutic agent comprises an immunotherapy.
  • identifying a unique B cell receptor comprises: obtaining cells from a biopsy; extracting RNA from the cells; synthesizing cDNA from the extracted RNA; and sequencing the cDNA. In some embodiments, identifying a unique B cell receptor comprises cloning and sequencing circulating cell free DNA.
  • the putative B cell receptor ligand domain comprises a polypeptide of 30 amino acids or less. In some embodiments, the putative B cell receptor ligand domain comprises a polypeptide from a cyclopeptide library. In some embodiments, the putative B cell receptor ligand domain further comprises an Fc region.
  • T cell activation is measured by an increase in expression of CD69 or CD25. In some embodiments, T cell activation is measured by an increase in expression of a fluorescent protein reporter gene under the control of Jun, NF- ⁇ B and/or Rel.
  • the method is performed in 3 weeks or less.
  • the subject is determined to have lymphoma. In some embodiments, the subject is determined to have one or more single-nucleotide polymorphisms (SNPs) associated with lymphoma.
  • SNPs single-nucleotide polymorphisms
  • FIG. 1 is a schematic diagram showing the workflow for selection of ligands for the personalized follicular lymphoma CAR-T therapy.
  • a lymph node biopsy sample from a patient with Follicular lymphoma is isolated and the collected tumor cells are used for identification of the malignant BCR genes after which they are reconstituted as a membrane bound BCR using PDGFR as a membrane anchor.
  • the reconstituted malignant BCR, co-expressed with the cyclopeptide-CAR library on the surface of the Jurkat cell line are used as a reporter-cell system for selection of the tumor cell targeting ligand.
  • the selected peptide ligands fused to the chimeric antigen receptor are sequenced and may be immediately used for generation of the therapeutic T lymphocytes modified by tumor-specific CAR.
  • the sequences top to bottom correspond to SEQ ID NOs: 31 and 32.
  • FIGS. 2A-2C shows autocrine-based selection of malignant FL-BCR ligands.
  • FIG. 2A shows the reporter system format.
  • FIG. 2B is flow cytometry data showing verification of the reporter cell assay by Myc-CAR/anti-Myc antibody pair interaction.
  • FIG. 2C shows that patient BCR-specific peptides on CAR activate reporter Jurkat cells transduced by membrane tethered follicular lymphoma BCRs.
  • FIGS. 3A-3D are graphs showing the selected peptide ligands specifically interact with the FL-BCRs and redirects CTLs to kill tumor cells.
  • FIG. 3A is a series of histograms showing SPR analysis of the interaction of the selected cyclopeptides CILDLPKFC (FL1) (SEQ ID NO: 1), CMPHWQNHC (FL2) (SEQ ID NO: 2), and CTTDQARKC (FL3) (SEQ ID NO: 3) and the malignant BCR.
  • FL1 SEQ ID NO: 1
  • CMPHWQNHC FL2
  • CTTDQARKC FL3
  • FIG. 3B is a series of graphs showing % cell lysis. FL-CARTs were co-cultured with Raji cells transduced with different lymphoma BCRs. Mock transduced T cells and CD19-CART was used as a comparison. Cytotoxicity was determined by measuring lactate dehydrogenase release after 6 hours.
  • FIG. 3C shows cells from the patient's biopsy or control B-cells were stained with the synthetic biotinylated FL1 peptide.
  • FIG. 3D is a graph showing lysis of B cells derived from the lymphoma biopsy sample by FL1-CART compared to Myc-CART and Mock transduced T cells.
  • FIGS. 4A-4F show CTLs re-directed by FL1-CAR suppress lymphomagenesis in vivo.
  • FIG. 4A is a schematic diagram showing experimental design indicating the engraftment of NOD SCID mice with 5 ⁇ 10 6 Raji-FL1 cells. At day 15, animals (12 per group) were randomized according to the tumor volume and received i.v. 3 ⁇ 10 6 FL1-CART, CD19-CAR or Myc-CART per mouse at day 17.
  • FIG. 4B is a series of graphs showing transduction efficacy of activated, CD3/CD28 bead-expanded human CD8 + T-cells with lentiviral based vectors expressing FL1-CAR, Myc-CAR and CD19-CAR constructs.
  • FIG. 4E shows flow cytometry analysis of the phenotype of FL1-CART cells prior to injection and on day 21 following the injection.
  • FIG. 4F is a graph showing relative percentages of na ⁇ ve, central memory and effector memory CART on day 21 following the injection.
  • FIGS. 5A-5C illustrate the structure of the reconstituted malignant BCR and combinatorial cyclopeptide library.
  • FIG. 5A shows amino acid sequences of the combinatorial cyclopeptide library fused with chimeric antigen receptors signaling domains. The sequence corresponds to SEQ ID NO: 33.
  • FIG. 5B shows reconstituted malignant BCR fused with the IgG1 Fc hinge and membrane-spanning PDGFR domain. The sequence corresponds to SEQ ID NO: 34.
  • FIG. 5C shows a schematic representation of secreted molecules.
  • FIG. 6 shows that FL-CARTs do not eliminate Raji cells without exogenous lymphoma BCR. Only CD-19 CART showed killing activity on regular Raji cells. Minimum unspecific lysis was observed when FL1-CAR, FL2-CAR and FL3-CAR T cells were incubated with Raji cells. Cytotoxicity was determined by measuring lactate dehydrogenase release after 6 hours.
  • FIGS. 7A-7C shows that CTLs redirected by FL1-CAR infiltrate solid tumors and prevent xenograft metastasis.
  • FIG. 7A shows bioluminescent imaging of organ-specific metastasis of Raji-FL1 cells (green, indicated by arrows) on day 35 after tumor implantation in mice treated by CD19-CART, FL1-CART and Myc-CART. For the Raji-FL1 cells detection mice received i.p. injection of the D-luciferine.
  • FIG. 7B shows histopathological changes analysis in tumors from CD19-CART, FL1-CART or Myc-CART treated animals. For identification of the histopathological changes tumors were stained with Hematoxylin-Eosin.
  • Lymphoma B cells with basophilic cytoplasm and high mitotic rate are indicated as black arrows, right panel.
  • Macrophages containing cellular debris giving the characteristic “starry sky” appearance are indicated by red arrows, right panel.
  • Cells thought to be in the state of apoptosis are indicated by arrows, left panel.
  • FIG. 7C shows immunohistochemical analysis of CD19-CART, FL1-CART or Myc-CART infiltration into the tumor (black arrows).
  • the human CD8-specific antibodies were used for CART staining.
  • FIGS. 8A-8E show that malignant B cell receptor recognizes self-antigen myoferlin.
  • FIG. 8A shows a schematic representation of myoferlin-driven autoreactive lymphomagenesis.
  • FIG. 8B shows PCR analysis of bcl-2 rearrangement in FL patient 1 biopsy sample. Staining of HEp-2 cells ( FIG. 8C ) and myoferlin-expressing HEK293T cells ( FIG. 8D ) with soluble malignant BCR is shown.
  • Shown in FIG. 8E is an alignment of the amino acid sequences of the identified malignant-specific peptide FL1 with the protein Myoferlin and surface proteins from Streptococcus mitis and Pneumocytis jirovecii . The sequences from top to bottom correspond to SEQ ID NOs: 1, 35, 36, and 37.
  • FIG. 9 shows percentages of hCD45+ lymphocytes, CD3+ T cells and CD19+ B cells in the lymphoid gate of PBMC at different time points following transplant.
  • FIG. 10 shows percentages of CD4+ and CD8+ human T cell subsets in the PBMC at different time points following transplant.
  • FIG. 11 shows levels of human IgM and IgG in humanized mice plasma at different time points following transplant.
  • FIG. 12 shows tumor growth kinetics in experimental groups.
  • FIG. 13 shows quantity of CAR T cells on day 38.
  • FIG. 14 shows levels of hCD45+ lymphocytes, CD3+ T cells and CD19+ B cells in the lymphoid gate in PBMC.
  • FIG. 15 shows percentages of CD4+ and CD8+ human T cell subsets in the PBMC.
  • FIG. 16 shows levels of human IgM and IgG in mice plasma at different time points following transplant.
  • FIG. 17 shows the CAR T lentiviral vector.
  • FIG. 18 shows tumor growth kinetics in experimental groups.
  • FIG. 19 shows NNK coding moiety flanked by Cysteines used in the Phage Display Cyclopeptide Library Kit used in Example 3. The sequences from top to bottom correspond to SEQ ID NOs: 38, 39, and 40.
  • FIG. 20 shows ELISA results for the binding of phages resulting from I-III rounds of panning as described in Example 3 against the BCR of patient FL1 with the BCR of patients FL1 and FL5.
  • Phage concentrations are, from left to right, 5, 2.5, 1.25, 0.63, and 0.31 mk/well for each round of panning for each antibody shown.
  • the disclosure provides methods for treatment of B cell malignancies using personalized medicine. More particularly, the methods provide for isolating a B cell receptor from a B cell malignancy in a subject, identifying a ligand for the B cell receptor, and then treating the subject with the B cell receptor ligand coupled to a therapeutic agent, e.g., a CART cell in which the B cell receptor ligand comprises the antigen binding domain.
  • the methods of the disclosure use an autocrine-based format to identify B cell receptor ligands specific to a tumor. By co-expressing a B cell receptor and a library of putative B cell receptor ligands, a B cell receptor ligand can be identified by its binding to the B cell receptor.
  • the B cell receptor ligand can be identified by phage display.
  • the B cell receptor ligand can be an effective therapeutic when coupled to a therapeutic agent because it can target the therapeutic agent to the B cell malignancy by binding the B cell receptor.
  • the methods described herein are particularly useful for treating B cell malignancies because B cell tumors are clonal populations having B cell receptors that are present in all of the cells of the tumor and only in the cells of the tumor. This allows for the identification of a personalized therapeutic target with no or very little off target effects.
  • the methods described herein utilize autocrine signaling.
  • the methods described herein make use of autocrine signaling to identify novel therapeutics for treating B cell malignancies.
  • autocrine signaling refers to a form of cell signaling in which a cell secretes a hormone or chemical messenger, e.g., an antigen, that binds to autocrine receptors, e.g., B cell receptors, on that same cell, leading to changes in the cell.
  • B cell receptor ligands may be identified by co-expressing a B cell receptor from a tumor and a CAR in a T cell, where the extracellular domain of the CAR comprises a peptide from a combinatorial peptide library. Activation of the T cell by the CAR indicates that the extracellular domain of the CAR has bound the B cell receptor and the peptide from the peptide library is a B cell ligand.
  • a patient can be treated with the ligand attached to a therapeutic agent.
  • Therapeutic agents can comprise chemotherapeutic drugs, immunotherapy, or radioactive isotopes.
  • a CAR comprising the B cell receptor ligand can comprise a therapeutic agent.
  • the CAR can be the same CAR used to identify the B cell receptor ligand, allowing for particularly fast identification of a personalized therapeutic target and synthesis of personalized medicine.
  • the whole process, from diagnosis to treatment can be completed in a short period of time, e.g., within several weeks.
  • the disclosure also provides methods for treatment of cancer by administering CAR-expressing T-cells, wherein the CAR comprises an antigen binding domain that specifically binds a cancer-specific antigen in a cancer-specific manner; and a vaccine comprising a polypeptide or a nucleic acid expressing the same cancer-specific antigen, or a cancer-specific fragment thereof. It has surprisingly been discovered that when a CAR specific for a cancer antigen and that same antigen are administered to a subject, the two have a synergistic effect on a reduction in tumor volume.
  • the CAR-expressing T cells comprise the CAR with the putative B cell receptor ligand, and the vaccine comprises a fragment or all of the B cell receptor.
  • the CAR-expressing T cells comprise an antibody fragment to an antigen that is specific to cancer cells and the vaccine comprises a fragment or all of that same antigen.
  • the B-cell receptor or BCR is a transmembrane receptor protein located on the outer surface of B cells.
  • the receptor's binding moiety is composed of a membrane-bound antibody that, like all antibodies, has a unique and randomly determined antigen-binding site generated by V(D)J recombination.
  • CD79 The BCR complexes with CD79, a transmembrane protein, and generates a signal following recognition of antigen by the BCR.
  • CD79 is composed of two distinct chains, CD79A and CD79B, which form a heterodimer on the surface of a B cell stabilized by disulfide bonding.
  • CD79a and CD79b are both members of the immunoglobulin superfamily.
  • Both CD79 chains contain an immunoreceptor tyrosine-based activation motif (ITAM) in their intracellular tails that they use to propagate a signal in a B cell, in a similar manner to CD3-generated signal tranduction observed during T cell receptor activation on T cells.
  • ITAM immunoreceptor tyrosine-based activation motif
  • an antibody refers to a protein that includes at least one immunoglobulin variable domain or immunoglobulin variable domain sequence.
  • an antibody can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region (abbreviated herein as VL).
  • an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions.
  • An antibody can have the structural features of IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof).
  • VH and VL regions can be further subdivided into regions of hypervariability, termed “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, termed “framework regions” (“FR”).
  • CDR complementarity determining regions
  • FR framework regions
  • the extent of the framework region and CDRs has been precisely defined (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, see also www.hgmp.mrc.ac.uk). Kabat definitions are used herein.
  • Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR
  • the VH or VL chain of the antibody can further include a heavy or light chain constant region, to thereby form a heavy or light immunoglobulin chain, respectively.
  • the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are inter-connected by, e.g., disulfide bonds.
  • the heavy chain constant region includes three immunoglobulin domains, CH1, CH2 and CH3.
  • B-cell malignancies represent a diverse collection of diseases, including most non-Hodgkin's lymphomas (NHL), some leukemias, and myelomas. Examples include chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma. B cell malignancies can be characterized as indolent or aggressive. Indolent malignancies, such as follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma, are characterized by slow growth and a high initial response rate, followed by a relapsing and progressive disease course. Aggressive lymphomas, such as diffuse large B-cell lymphoma, mantle cell lymphoma and Burkitt's lymphoma, are characterized by rapid growth and lower initial response rates, with shorter overall survival (OS).
  • OS overall survival
  • B cell malignancies are characterized in that they are clonal populations of B cells. Since they are clonal populations of B cells, each cancerous cell in the population of cancer cells, e.g., a tumor, has the same B cell receptor. As such, B cell receptors on cancerous cells are tumor specific antigens that can be targeted by the ligand (or “antigen”) of the BCR.
  • BCR ligands can be used, for example, as a cancer treatment.
  • Therapeutic agents can be targeted to cancer cells via the interaction between the BCR and the BCR ligand.
  • the methods described herein comprise identifying or providing a B cell receptor, e.g., expressed in cancer cells.
  • identifying or providing a B cell receptor comprises acquiring a sample from a subject.
  • the sample is a fluid sample, e.g., blood.
  • the sample is a tissue sample.
  • the sample comprises a, e.g., a tumor sample or a biopsy.
  • the biopsy is a lymph node biopsy.
  • the sample is from a subject having or suspected of having cancer.
  • the cancer is a B cell malignancy.
  • the cancer is a lymphoma.
  • the cancer is selected from diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone B-cell lymphoma (MZL) or mucosa-associated lymphatic tissue lymphoma (MALT), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Burkitt's lymphoma, lymphoplasmacytic lymphoma, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, primary central nervous system lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B-cell
  • DLBCL diffuse large B-cell lymphom
  • the subject is determined to have any of the cancers described herein. In some embodiments, the subject is determined to have a B cell malignancy. In some embodiments, the subject is determined to have lymphoma. In some embodiments, the subject is determined to have one or more single-nucleotide polymorphisms associated with cancer, e.g., a B cell malignancy and/or lymphoma.
  • single-nucleotide polymorphism refers to a DNA sequence variation occurring when a single nucleotide—A, T, C or G—in the genome (or other shared sequence) differs between members of a biological species or paired chromosomes in an individual.
  • identifying or providing a B cell receptor comprises extracting RNA out of the cells of the sample.
  • Methods for extracting RNA out of cells are well known to those of skill in the art and include, for example, phenol/chlorophorm based extraction methods, or the use of the RNAeasy KitTM (Qiagen).
  • identifying or providing a B cell receptor comprises synthesizing cDNA out of extracted RNA.
  • Methods for producing cDNA are well known to those of skill in the art and comprises the formation of cDNA from mRNA by reverse transcriptase.
  • identifying or providing a B cell receptor comprises sequencing the cDNA.
  • the type of sequencing performed can be, for example, pyrosequencing, single-molecule real-time sequencing, ion torrent sequencing, sequencing by synthesis, sequencing by ligation (SOLiDTM), and chain termination sequencing (e.g., Sanger sequencing).
  • Sequencing methods are known in the art and commercially available (see, e.g., Ronaghi et al.; Uhlén, M; Nyrén, P (1998). “A sequencing method based on real-time pyrophosphate”.
  • the B cell receptor is cloned into an expression vector for expressing the B cell receptor in T cells using methods described herein.
  • the B cell receptor is cloned into an scFv format using a vector, e.g., a pComb3X vector.
  • the scFv form of the B cell receptor is cloned into a vector for expressing the antibody molecules as dimers with the variable region in the plasma membrane with their binding sites facing the solvent.
  • the scFv form of the B cell receptor is cloned into a vector containing a linker.
  • the linker is a a flexible linker to a membrane-spanning domain of the platelet-derived growth factor receptor.
  • the vector further comprises a constant domain of antibody, e.g., Fc, e.g., IgG1 Fc.
  • the methods described herein comprise identifying a B cell receptor ligand. Once the B cell receptor is identified, the ligand of the B cell receptor is identified by contacting the B cell receptor with putative B cell receptor ligands, e.g., a library of putative B cell receptor ligands.
  • putative B cell receptor ligands e.g., a library of putative B cell receptor ligands.
  • the methods described herein provide for co-expressing B cell receptors and a library of putative B cell receptor ligands in cells, e.g., T cells, and detecting binding of the B cell receptor to a putative B cell receptor ligand, thereby identifying a unique B cell receptor ligand.
  • detecting binding comprises measuring the level of B cell receptor signaling.
  • B cell receptor and a putative B cell receptor ligand are both expressed, e.g., in a B cell, if the putative B cell receptor ligand is a ligand of the B cell receptor, the binding of the B cell receptor will initiate a signaling cascade.
  • detecting binding comprises measuring the expression of genes regulated by BCR signaling.
  • the methods described herein provide for co-expressing B cell receptors and a library of CARs comprising putative B cell receptor ligand domains in T cells and detecting binding of the B cell receptor to a putative B cell receptor ligand by identifying activation of the T cell by the CAR, thereby identifying a unique B cell receptor ligand.
  • T cells are transduced or transfected with nucleic acids encoding B cell receptors and CARs and T cell activation is measured after a period of time. In some embodiments, T cell activation is measured 2, 4, 6, 8, 12, 16, or 20 hours, or 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 days after transduction or transfection, e.g., 2 days after transduction or transfection.
  • co-expressing the B cell receptors and CARs comprises culturing T cells transduced or transfected with nucleic acids encoding B cell receptors and CARs in culture media.
  • Media for culturing T cells are well known to those of skill in the art.
  • T cells are cultured in DMEM or RPMI medium.
  • the medium is supplemented with FBS, e.g, 5-20% FBS, e.g., 10% FBS.
  • the medium is supplemented with HEPES, e.g., 1-100 mM HEPES, e.g., 10 mM HEPES.
  • the medium is supplemented with penicillin, e.g., 10-500 U/ml penicillin, e.g., 100 U/ml penicillin.
  • the medium is supplemented with streptomycin, e.g., 10-500 ug/ml streptomycin, e.g., 100 ug/ml streptomycin.
  • the medium is supplemented with L-alanyl-L-glutamine, e.g., 0.1-10 mM L-alanyl-L-glutamine, e.g., 2 mM L-alanyl-L-glutamine.
  • measuring the level of T cell activation comprises measuring the nucleic acid or protein level of a gene expressed in activated T cells.
  • genes downregulated during T cell activation include, for example, L-selectin, CD127, and BCL-2.
  • genes downregulated during T cell activation include, for example CD69, CD25, CD40L, CD44, Ki67, and KLRG1.
  • the T cell comprises a fluorescent protein reporter gene under the control of a transcription factor that activates transcription when the T cell is activated and measuring activation comprises measuring the amount of fluorescent protein produced.
  • the transcription factor is Jun, NF- ⁇ B or Rel.
  • Gene expression can be measured at either the RNA or protein level.
  • Assays for detecting RNA include, but are not limited to, Northern blot analysis, RT-PCR, sequencing technology, RNA in situ hybridization (using e.g., DNA or RNA probes to hybridize RNA molecules present in the sample), in situ RT-PCR (e.g., as described in Nuovo G J, et al. Am J Surg Pathol. 1993, 17: 683-90; Karlinoth P, et al. Pathol Res Pract.
  • oligonucleotide microarray e.g., by hybridization of polynucleotide sequences derived from a sample to oligonucleotides attached to a solid surface (e.g., a glass wafer with addressable location, such as Affymetrix microarray (Affymetrix®, Santa Clara, Calif.)).
  • Assays for detecting protein levels include, but are not limited to, immunoassays (also referred to herein as immune-based or immuno-based assays, e.g., Western blot, ELISA, proximity extension assays, and ELISpot assays), Mass spectrometry, and multiplex bead-based assays.
  • immunoassays also referred to herein as immune-based or immuno-based assays, e.g., Western blot, ELISA, proximity extension assays, and ELISpot assays
  • Mass spectrometry mass spectrometry
  • multiplex bead-based assays include multiplexed immunoassays as described for example in U.S. Pat. Nos. 6,939,720 and 8,148,171, and published U.S. Patent Application No. 2008/0255766, and protein microarrays as described for example in published U.S. Patent Application No. 2009/0088329.
  • protocols for identifying activated T cells allow for the identification of activated T cells and the separation of activated T cells from unactivated T cells.
  • flow cytometry generally, and Fluorescence-activated cell sorting (FACS) in particular, are readily known to those of skill in the art for the purpose of cell sorting based on a variety of properties.
  • FACS Fluorescence-activated cell sorting
  • a heterogeneous mixture of biological cells can be sorted into two or more containers, one cell at a time, based upon the specific light scattering and fluorescent characteristics of each cell.
  • T cell activation can be measured by levels of a fluorescently marked or labeled transcript or protein.
  • the expression level of a protein e.g., a cell surface localized protein, e.g., a protein upregulated or downregulated in activated T cells described herein, can be measured by contacting the cells with an antibody coupled, covalently or non-covalently, to a fluorescent label.
  • the antibody targets the protein upregulated or downregulated in activated T cells.
  • activated T cells can be identified by binding of the T cells to GFP-labeled anti-CD69 antibody.
  • detecting binding between a putative B cell receptor ligand and a cell expressing a B cell receptor comprises visualizing binding of the putative B cell receptor ligand to the cell expressing the B cell receptor.
  • the ligand is tagged to allow for visualization of the localization of the ligand. Suitable tags include, for example, fluorescent genes such as GFP, YFP, RFP and the like.
  • localization of the putative B cell receptor ligand to the cell expressing the B cell receptor can be assessed using any suitable method known by those of skill in the art, e.g., fluorescence microscopy, immunohistochemistry, or FACS.
  • a B cell receptor ligand binds to the cells expressing the B cell receptor and does not bind to the same cell type when the B cell receptor is not expressed.
  • the library pf putative B cell receptor ligands is contacted to the B cell receptor by phage display.
  • “Phage display” is a technique by which variant polypeptides are displayed as fusion proteins to a coat protein on the surface of phage, e.g. filamentous phage, particles.
  • a utility of phage display lies in the fact that large libraries of randomized protein variants can be rapidly and efficiently sorted for those sequences that bind to a target molecule with high affinity. Display of peptides and proteins libraries on phage has been used for screening millions of polypeptides for ones with specific binding properties. Polyvalent phage display methods have been used for displaying small random peptides and small proteins through fusions to either gene III or gene VIII of filamentous phage. Wells and Lowman, Curr. Opin. Struct.
  • phagemid vectors are used, which simplify DNA manipulations. Lowman and Wells, Methods: A companion to Methods in Enzymology, 1991, 3:205-216.
  • Phage display of proteins, peptides and mutated variants thereof including constructing a family of variant replicable vectors containing a transcription regulatory element operably linked to a gene fusion encoding a fusion polypeptide, transforming suitable host cells, culturing the transformed cells to form phage particles which display the fusion polypeptide on the surface of the phage particle, contacting the recombinant phage particles with a target molecule so that at least a portion of the particle bind to the target, separating the particles which bind from those that do not are known and may be used with the transformation method of the invention. See U.S. Pat. No. 5,750,373; WO 97/09446; U.S. Pat. Nos.
  • putative B cell receptor ligands capable of binding to the B cell receptor as described herein are isolated from a suitable library.
  • exemplary putative B cell receptor ligand libraries include phage-peptide libraries such as New England Biolabs Ph.D.-7 and Ph.D.-12 libraries. Methods of generating peptide libraries and screening these libraries are also disclosed in U.S. Pat. Nos.
  • a putative B cell receptor ligand library can be probed with the target B cell receptor or a fragment thereof and members of the library that are capable of binding to the B cell receptor can be isolated, typically by retention on a support.
  • Such screening process may be performed by multiple rounds (e.g., including both positive and negative selections) to enrich the pool of putative B cell receptor ligands capable of binding to the B cell receptor.
  • negative selection is performed in each round of panning. Individual clones of the enriched pool can then be isolated and further characterized to identify those having desired binding activity and biological activity. Sequences of the putative B cell receptor ligands can also be determined via conventional methodology.
  • phage displays typically use a covalent linkage to bind the protein (e.g., putative B cell receptor ligand domain) component to a bacteriophage coat protein.
  • the linkage results from translation of a nucleic acid encoding the putative B cell receptor ligand domain component fused to the coat protein.
  • the linkage can include a flexible peptide linker, a protease site, or an amino acid incorporated as a result of suppression of a stop codon.
  • Phage display is described, for example, in U.S. Pat. No.
  • Bacteriophage displaying the putative B cell receptor ligand domain component can be grown and harvested using standard phage preparatory methods, e.g. PEG precipitation from growth media. After selection of individual display phages, the nucleic acid encoding the selected protein components can be isolated from cells infected with the selected phages or from the phage themselves, after amplification. Individual colonies or plaques can be selected, and then the nucleic acid may be isolated and sequenced.
  • each isolated library member can be also tested for its ability to bind to a non-target molecule to evaluate its binding specificity.
  • non-target molecules include streptavidin on magnetic beads, blocking agents such as bovine serum albumin, non-fat bovine milk, soy protein, any capturing or target immobilizing monoclonal antibody, or non-transfected cells which do not express the target.
  • a high-throughput ELISA screen can be used to obtain the data, for example.
  • the ELISA screen can also be used to obtain quantitative data for binding of each library member to the target as well as for cross species reactivity to related targets or subunits of the target antigen and also under different condition such as pH 6 or pH 7.5.
  • the non-target and target binding data are compared (e.g., using a computer and software) to identify library members that specifically bind to the target.
  • identifying unique B cell receptor ligands e.g., for cancer therapy, comprising identifying a putative unique B cell receptor ligand as binding a unique B cell receptor.
  • the putative B cell receptor ligand comprises a polypeptide. In some embodiments, a putative B cell receptor ligand comprises a cyclopeptide. In some embodiments, a putative B cell receptor ligand comprises a peptoid. In some embodiments, a putative B cell receptor ligand comprises a cyclopeptoid. In some embodiments, the putative B cell receptor ligand comprises a polysaccharide. In some embodiments, the putative B cell receptor ligand comprises a lipid. In some embodiments, the putative B cell receptor ligand comprises a small molecule.
  • the putative B cell receptor ligand comprises an amino acid sequence that encodes a portion or all of a cellular protein. In some embodiments, the putative B cell receptor ligand comprises an amino acid sequence that does not encode a portion or all of a cellular protein.
  • the putative B cell receptor ligand is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 amino acids in length, e.g., 9 amino acids in length. In some embodiments, the putative B cell receptor ligand is less than 20, less than 15, or less than 10 amino acids in length. In some embodiments, the putative B cell receptor ligand is 2-20, 5-15, or 7-10 amino acids in length.
  • the putative B cell receptor ligand comprises the sequence YX n Z. In some embodiments, Y and Z are polar uncharged amino acids. In some embodiments, Y and Z are C or conservative substitutions of C, e.g., S, A, M, or T. In some embodiments, the putative B cell receptor ligand comprises the sequence CX n C. In some embodiments, the putative B cell receptor ligand comprises the sequence SX n S. In some embodiments, the putative B cell receptor ligand comprises the sequence CX n S. In some embodiments, the putative B cell receptor ligand comprises the sequence SX n C. In some embodiments, X is any of the 20 amino acids encoded by DNA.
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, e.g., n is 7. In some embodiments, n is 15 or less, 12 or less, or 9 or less. In some embodiments, n is 2-15, 5-10, or 6-8. In some embodiments, the putative B cell receptor ligand comprises any of SEQ ID NOs: 1-3.
  • the putative B cell receptor ligand comprises a cyclopeptide with the sequence CX n C, and the N- and C-terminal Cys form a Cys-Cys interaction, circularizing the cyclopeptide.
  • the library of putative B cell receptor ligands is generated from a cDNA library and with each putative B cell receptor ligand comprising a portion or all of a cDNA.
  • the library of putative B cell receptor ligands comprises a peptide library.
  • the peptide library is a combinatorial peptide library.
  • the putative B cell receptor ligands in the peptide library comprises the sequence YX n Z with the putative B cell receptor ligands differing in X n sequence.
  • Y and Z are polar uncharged amino acids.
  • Y and Z are C or conservative substitutions of C, e.g., S, A, M, or T.
  • the putative B cell receptor ligands in the peptide library comprises the sequence CX n C with the putative B cell receptor ligands differing in X n sequence. In some embodiments, the putative B cell receptor ligands in the peptide library comprises the sequence SX n S with the putative B cell receptor ligands differing in X n sequence. In some embodiments, the putative B cell receptor ligands in the peptide library comprises the sequence CX n S with the putative B cell receptor ligands differing in X n sequence.
  • the putative B cell receptor ligands in the peptide library comprises the sequence SX n C with the putative B cell receptor ligands differing in X n sequence.
  • X is any of the 20 amino acids encoded by DNA.
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, e.g., n is 7.
  • n is 15 or less, 12 or less, or 9 or less.
  • n is 2-15, 5-10, or 6-8.
  • X n sequence is generated by PCR with oligonucleotides having degenerate NNN, NNK, or NNS codons at the X positions.
  • the degenerate codons are NNK codons.
  • the putative B cell receptor ligand comprises the antigen binding domain of a CAR. In some embodiments the putative B cell receptor ligand is linked to a phage, e.g., as a component of a phage display library.
  • an exemplary CAR construct disclosed herein comprise an optional leader sequence, an extracellular putative B cell receptor ligand domain, a hinge, a transmembrane domain, and an intracellular stimulatory domain.
  • an exemplary CAR construct comprises an optional leader sequence, an extracellular putative B cell receptor ligand domain, a hinge, a transmembrane domain, an intracellular costimulatory domain and an intracellular stimulatory domain.
  • CAR Chimeric Antigen Receptor
  • a “CAR” refers to a recombinant polypeptide construct comprising at least an extracellular ligand domain, a transmembrane domain and a cytoplasmic signaling domain (also referred to herein as “an intracellular signaling domain”) comprising a functional signaling domain derived from a stimulatory molecule as defined below.
  • the domains in the CAR polypeptide construct are in the same polypeptide chain, e.g., comprise a chimeric fusion protein.
  • the domains in the CAR polypeptide construct are not contiguous with each other.
  • the CAR described herein comprises an extracellular domain.
  • the extracellular domain comprises an antigen binding domain.
  • the antigen binding domain is a putative B cell receptor ligand domain comprising a putative B cell receptor ligand, e.g., a putative B cell receptor ligand described herein.
  • a library of CARs with the CARs differing in their antigen binding domains, e.g., putative B cell receptor ligand domains.
  • each CAR within the library comprises a distinct antigen binding domain, e.g., putative B cell receptor ligand domain.
  • the library of CARs comprises an extracellular domain and the extracellular domain comprises the library of antigen binding domains, e.g., putative B cell receptor ligands described herein.
  • the putative B cell receptor ligand domain further comprises an Fc domain, which is CH2 and CH3 of a heavy chain constant region.
  • the Fc domain is from a heavy chain constant region chosen from, e.g., the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; particularly, chosen from, e.g., the (e.g., human) heavy chain constant regions of IgG1, IgG2, IgG3, and IgG4.
  • antigen binding domain comprises an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain sequence.
  • the term “antigen binding domain” encompasses antibodies and antibody fragments.
  • an antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope.
  • a multispecific antibody molecule is a bispecific antibody molecule.
  • a bispecific antibody has specificity for no more than two antigens.
  • a bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope.
  • the antigen binding domain specifically binds a cancer-specific antigen.
  • the CARs of the present invention includes CARs comprising an antigen binding domain (e.g., antibody or antibody fragment) that binds to a MHC presented peptide.
  • an antigen binding domain e.g., antibody or antibody fragment
  • peptides derived from endogenous proteins fill the pockets of Major histocompatibility complex (MHC) class I molecules, and are recognized by T cell receptors (TCRs) on CD8+T lymphocytes.
  • TCRs T cell receptors
  • the MHC class I complexes are constitutively expressed by all nucleated cells.
  • virus-specific and/or tumor-specific peptide/MHC complexes represent a unique class of cell surface targets for immunotherapy.
  • TCR-like antibodies targeting peptides derived from viral or tumor antigens in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 have been described (see, e.g., Sastry et al., J Virol. 2011 85(5):1935-1942; Sergeeva et al., Blood, 2011 117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 2001 8(21):1601-1608; Dao et al., Sci Transl Med 2013 5(176):176ra33; Tassev et al., Cancer Gene Ther 2012 19(2):84-100).
  • TCR-like antibody can be identified from screening a library, such as a human scFv phage displayed library.
  • the antigen binding domain can be any protein that binds to the antigen including but not limited to a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, and a functional fragment thereof, including but not limited to a single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived nanobody, and to an alternative scaffold known in the art to function as antigen binding domain, such as a recombinant fibronectin domain, and the like.
  • VH heavy chain variable domain
  • VL light chain variable domain
  • VHH variable domain
  • the antigen binding domain comprises a human antibody or an antibody fragment.
  • the antigen binding domain comprises a humanized antibody or an antibody fragment.
  • a humanized antibody can be produced using a variety of techniques known in the art, including but not limited to, CDR-grafting (see, e.g., European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089, each of which is incorporated herein in its entirety by reference), veneering or resurfacing (see, e.g., European Patent Nos.
  • framework substitutions are identified by methods well-known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; and Riechmann et al., 1988, Nature, 332:323, which are incorporated herein by reference in their entireties.)
  • a humanized antibody or antibody fragment has one or more amino acid residues remaining in it from a source which is nonhuman. These nonhuman amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain.
  • humanized antibodies or antibody fragments comprise one or more CDRs from nonhuman immunoglobulin molecules and framework regions wherein the amino acid residues comprising the framework are derived completely or mostly from human germline.
  • an antigen binding domain is derived from a display library.
  • a display library is a collection of entities; each entity includes an accessible polypeptide component and a recoverable component that encodes or identifies the polypeptide component.
  • the polypeptide component is varied so that different amino acid sequences are represented.
  • the polypeptide component can be of any length, e.g. from three amino acids to over 300 amino acids.
  • a display library entity can include more than one polypeptide component, for example, the two polypeptide chains of a Fab.
  • a display library can be used to identify an antigen binding domain. In a selection, the polypeptide component of each member of the library is probed with the antigen, or a fragment there, and if the polypeptide component binds to the antigen, the display library member is identified, typically by retention on a support.
  • Retained display library members are recovered from the support and analyzed.
  • the analysis can include amplification and a subsequent selection under similar or dissimilar conditions. For example, positive and negative selections can be alternated.
  • the analysis can also include determining the amino acid sequence of the polypeptide component and purification of the polypeptide component for detailed characterization.
  • a variety of formats can be used for display libraries. Examples include the phage display.
  • the protein component is typically covalently linked to a bacteriophage coat protein.
  • the linkage results from translation of a nucleic acid encoding the protein component fused to the coat protein.
  • the linkage can include a flexible peptide linker, a protease site, or an amino acid incorporated as a result of suppression of a stop codon.
  • Phage display is described, for example, in U.S. Pat. No.
  • Bacteriophage displaying the protein component can be grown and harvested using standard phage preparatory methods, e.g. PEG precipitation from growth media. After selection of individual display phages, the nucleic acid encoding the selected protein components can be isolated from cells infected with the selected phages or from the phage themselves, after amplification. Individual colonies or plaques can be picked, the nucleic acid isolated and sequenced.
  • display formats include cell based display (see, e.g., WO 03/029456), protein-nucleic acid fusions (see, e.g., U.S. Pat. No. 6,207,446), ribosome display, and E. coli periplasmic display.
  • the CAR comprises a leader sequence at the amino-terminus (N-ter) of the antigen binding domain. In one aspect, the CAR further comprises a leader sequence at the N-terminus of the antigen binding domain, wherein the leader sequence is optionally cleaved from the antigen binding domain (e.g., aa scFv) during cellular processing and localization of the CAR to the cellular membrane. In some embodiments, the leader sequence is an interleukin 2 signal peptide.
  • the transmembrane domain may be derived either from a natural or from a recombinant source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. In one aspect the transmembrane domain is capable of signaling to the intracellular domain(s) whenever the CAR has bound to a target.
  • a transmembrane domain of particular use in this invention may include at least the transmembrane region(s) of e.g., the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8 (e.g., CD8 alpha, CD8 beta), CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154.
  • CD8 e.g., CD8 alpha, CD8 beta
  • CD9 CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154.
  • a transmembrane domain may include at least the transmembrane region(s) of, e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2R gamma, IL7R a, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, rfGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (
  • the transmembrane domain can be attached to the extracellular region of the CAR, e.g., the ligand domain of the CAR, via a hinge, e.g., a hinge from a human protein.
  • a hinge e.g., a hinge from a human protein.
  • the hinge can be a human Ig (immunoglobulin) hinge, e.g., an IgG4 hinge, or a CD8a hinge.
  • the cytoplasmic domain or region of the present CAR includes an intracellular signaling domain.
  • An intracellular signaling domain is capable of activation of at least one of the normal effector functions of the immune cell in which the CAR has been introduced.
  • intracellular signaling domains for use in the CAR of the invention include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivative or variant of these sequences and any recombinant sequence that has the same functional capability.
  • TCR T cell receptor
  • T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary intracellular signaling domains) and those that act in an antigen-independent manner to provide a secondary or costimulatory signal (secondary cytoplasmic domain, e.g., a costimulatory domain).
  • intracellular signaling domain refers to an intracellular portion of a molecule.
  • the intracellular signaling domain can generate a signal that promotes an immune effector function of the CAR containing cell, e.g., a CART cell or CAR-expressing NK cell.
  • immune effector function e.g., in a CART cell or CAR-expressing NK cell
  • examples of immune effector function include cytolytic activity and helper activity, including the secretion of cytokines.
  • the intracellular signal domain transduces the effector function signal and directs the cell to perform a specialized function. While the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain.
  • intracellular signaling domain can comprise a primary intracellular signaling domain.
  • exemplary primary intracellular signaling domains include those derived from the molecules responsible for primary stimulation, or antigen dependent simulation.
  • the intracellular signaling domain can comprise a costimulatory intracellular domain.
  • Exemplary costimulatory intracellular signaling domains include those derived from molecules responsible for costimulatory signals, or antigen independent stimulation.
  • a primary intracellular signaling domain can comprise a cytoplasmic sequence of a T cell receptor
  • a costimulatory intracellular signaling domain can comprise cytoplasmic sequence from co-receptor or costimulatory molecule.
  • a primary intracellular signaling domain can comprise a signaling motif which is known as an immunoreceptor tyrosine-based activation motif or ITAM.
  • ITAM immunoreceptor tyrosine-based activation motif
  • Examples of ⁇ AM containing primary cytoplasmic signaling sequences include, but are not limited to, those derived from CD3 zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 (“ICOS”), FceRI, CD66d, DAP10, and DAP12.
  • the intracellular signalling domain of the CAR can comprise the primary signalling domain, e.g., CD3-zeta signaling domain, by itself or it can be combined with any other desired intracellular signaling domain(s) useful in the context of a CAR of the invention.
  • the intracellular signaling domain of the CAR can comprise a primary signalling domain, e.g., CD3 zeta chain portion, and a costimulatory signaling domain.
  • a costimulatory intracellular signaling domain refers to the intracellular portion of a costimulatory molecule.
  • the intracellular signaling domain can comprise the entire intracellular portion, or the entire native intracellular signaling domain, of the molecule from which it is derived, or a functional fragment thereof.
  • costimulatory molecule refers to the cognate binding partner on a T cell that specifically binds with a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation.
  • Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for an efficient immune response.
  • Examples of such molecules include a MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA
  • CD27 co-stimulation has been demonstrated to enhance expansion, effector function, and survival of human CART cells in vitro and augments human T cell persistence and antitumor activity in vivo (Song et al. Blood. 2012; 119(3):696-706).
  • the methods described herein comprise expressing B cell receptors and putative B cell receptor ligands, e.g., CARs comprising putative B cell receptor ligands, in cells, e.g., T cells for identifying a B cell receptor ligand, e.g., for treatment of cancer.
  • the methods described herein also comprise expressing CARs in T cells for cancer treatment.
  • the disclosure encompasses DNA constructs for expressing CARs in cells, e.g., T cells.
  • the nucleic acid sequences coding for the desired molecules can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells expressing the gene, by deriving the gene from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques.
  • sequences of B cell receptors can be derived from cancer cells.
  • Recombinant DNA and molecular cloning techniques used here are well known in the art and are described, for example, by Sambrook, J., Fritsch, E. F. and Maniatis, T.
  • the gene of interest can be produced synthetically, rather than cloned.
  • the present disclosure also provides vectors in which a DNA of the present disclosure is inserted.
  • Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells.
  • Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity.
  • the desired B cell receptor or CAR can be expressed in the cells by way of transposons.
  • a “lentivirus” as used herein refers to a genus of the Retroviridae family. Lenti viruses are unique among the retroviruses in being able to infect non-dividing cells; they can deliver a significant amount of genetic information into the DNA of the host cell, so they are one of the most efficient methods of a gene delivery vector. HIV, SIV, and FIV are all examples of lenti viruses. Vectors derived from lenti viruses offer the means to achieve significant levels of gene transfer in vivo.
  • Expression of natural or synthetic nucleic acids encoding B cell receptors and CARs is typically achieved by operably linking a nucleic acid encoding the polypeptide expressing the B cell receptor or CAR or portions thereof to a promoter, and incorporating the construct into an expression vector.
  • the vectors can be suitable for replication and integration into eukaryotes. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence.
  • the expression constructs of the disclosure may also be used for nucleic acid immunization and gene therapy, using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466, incorporated by reference herein in their entireties.
  • the disclosure provides a gene therapy vector.
  • the nucleic acid can be cloned into a number of types of vectors.
  • the nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid.
  • Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.
  • the expression vector may be provided to a cell in the form of a viral vector.
  • Viral vector technology is well known in the art and is described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in other virology and molecular biology manuals.
  • Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses.
  • a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers, (e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).
  • retroviruses provide a convenient platform for gene delivery systems.
  • a selected gene can be inserted into a vector and packaged in retroviral particles using techniques known in the art.
  • the recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo.
  • retroviral systems are known in the art.
  • retrovirus vectors are used.
  • retrovirus vectors are known in the art.
  • lentivirus vectors are used.
  • promoter elements e.g., enhancers
  • promoters regulate the frequency of transcriptional initiation.
  • these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well.
  • the spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another.
  • tk thymidine kinase
  • the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline.
  • individual elements can function either cooperatively or independently to activate transcription.
  • a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto.
  • CMV immediate early cytomegalovirus
  • EF-1a Elongation Factor-1a
  • constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter. Further, the disclosure is not limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the disclosure.
  • an inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired.
  • inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.
  • the promoter is a EF-1a promoter.
  • the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells.
  • the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells.
  • Useful selectable markers include, for example, antibiotic-resistance genes, such as neo and the like, and fluorescent genes such as GFP, YFP, RFP and the like.
  • reporter genes or selectable marker genes are excluded from a CAR polypeptide used in a therapy as described herein.
  • Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences.
  • a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, e.g., enzymatic activity, antibiotic resistance or fluorescence. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells.
  • Suitable reporter genes may include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene (e.g., Ui-Tei et al., 2000 FEBS Letters 479: 79-82).
  • Suitable expression systems are well known and may be prepared using known techniques or obtained commercially.
  • the construct with the minimal 5′ flanking region showing the highest level of expression of reporter gene is identified as the promoter.
  • Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription.
  • the vector can be readily introduced into a host cell, e.g., mammalian, bacterial, yeast, or insect cell by any method in the art.
  • the expression vector can be transferred into a host cell by physical, chemical, or biological means.
  • the host cell is a T cell.
  • Physical methods for introducing a polynucleotide into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). A preferred method for the introduction of a polynucleotide into a host cell is calcium phosphate transfection.
  • Biological methods for introducing a polynucleotide of interest into a host cell include the use of DNA and RNA vectors.
  • Viral vectors, and especially retroviral vectors have become the most widely used method for inserting genes into mammalian, e.g., human cells.
  • Other viral vectors can be derived from lentivirus, poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like. See, for example, U.S. Pat. Nos. 5,350,674 and 5,585,362.
  • Chemical means for introducing a polynucleotide into a host cell include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • colloidal dispersion systems such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • An example of a colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
  • cells are transfected with nucleic acids expressing a B cell receptor and/or a CAR.
  • transfected or “transformed” or “transduced” as used herein refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell.
  • a “transfected” or “transformed” or “transduced” cell is one which has been transfected, transformed or transduced with exogenous nucleic acid.
  • the cell includes the primary subject cell and its progeny.
  • the cells are mammalian cells. In some embodiments, the cells are human cells. In some embodiments, the cells are immune cells, e.g., B cells, T cells, or NK cells. In particular embodiments, the cells are T cells.
  • Immune cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors.
  • the immune cells e.g., T cells
  • any number of immune cell lines including but not limited to T cell lines, including, for example, Hep-2, Jurkat, and Raji cell lines, available in the art, may be used.
  • immune cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FicollTM separation.
  • cells from the circulating blood of an individual are obtained by apheresis.
  • the apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, NK cells, other nucleated white blood cells, red blood cells, and platelets.
  • the cells collected by apheresis may be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps.
  • the cells are washed with phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations.
  • initial activation steps in the absence of calcium lead to magnified activation.
  • a washing step may be accomplished by methods known to those in the art, such as by using a semi-automated “flow-through” centrifuge (for example, the Cobe 2991 cell processor, the Baxter CytoMate, or the Haemonetics Cell Saver 5) according to the manufacturer's instructions.
  • the cells may be resuspended in a variety of biocompatible buffers, such as, for example, Ca 2+ -free, Mg 2+ -free PBS, PlasmaLyte A, or other saline solution with or without buffer.
  • buffers such as, for example, Ca 2+ -free, Mg 2+ -free PBS, PlasmaLyte A, or other saline solution with or without buffer.
  • the undesirable components of the apheresis sample may be removed and the cells directly resuspended in culture media.
  • immune cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLLTM gradient or by counterflow centrifugal elutriation.
  • a specific subpopulation of T cells such as CD3 + , CD28 + , CD4 + , CD8 + , CD45RA + , and CD45RO + T cells, can be further isolated by positive or negative selection techniques.
  • Enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells.
  • One method is cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected.
  • a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8.
  • T regulatory cells are depleted by anti-C25 conjugated beads or other similar method of selection.
  • kits for treatment using the B cell receptor ligands identified herein are provided herein.
  • methods for rapid treatment of B cell malignancies allow for the rapid identification of a B cell receptor ligand by co-expressing a CAR having a putative B cell receptor ligand and a B cell receptor in a T cell, and identifying binding of the putative B cell receptor ligand to the B cell receptor by activation of the B cell, and in some embodiments, the same CAR used in identification of the B cell receptor ligand can be used for treatment, allowing for the rapid identification and treatment of B cell malignancies.
  • provided herein are methods of treatment using B cell receptor ligands that activate a T cell when a CAR comprising the B cell ligand is co-expressed with the B cell receptor of the lymphoma cells of a subject being treated in T cells.
  • a subject is treated with a B cell receptor ligand coupled to a therapeutic agent.
  • the B cell receptor ligand coupled to a therapeutic agent comprises a therapeutic CAR, e.g., a CAR described herein, expressed in a T cell as is described herein, e.g., a CAR-T cell.
  • the therapeutic CAR comprises a CAR used in a method of identifying a B cell receptor.
  • the CART cell e.g., a T cell expressing a CAR described herein, results in greater specificity and/or activity than a control.
  • the control comprises a CAR T cell.
  • the CAR T cell has an antigen binding domain specific for an antigen unrelated to cancer.
  • the CAR T cell has an antigen binding domain specific for a cancer-specific antigen, as is described herein.
  • activity and specificity can be demonstrated by cytotoxicity.
  • activity comprises cytotoxicity, e.g., as measured by % lysis, towards cells expressing the unique B cell receptor relative to a control.
  • the % lysis is 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, or more greater than a control.
  • specificity comprises cytotoxicity, e.g., as measured by % lysis, towards cells that do not express the unique B cell receptor.
  • the % lysis is 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, or more less than a control.
  • % lysis is measured at an effector:target ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, or greater.
  • subjects treated with the CART cell e.g., a T cell expressing a CAR described herein, exhibit reduced cytokine release syndrome (CRS) relative to a subject treated with a control.
  • CRS cytokine release syndrome
  • Coupled refers to the association of two molecules though covalently and non-covalent interactions, e.g., by hydrogen, ionic, or Van-der-Waals bonds. Such bonds may be formed between at least two of the same or different atoms or ions as a result of redistribution of electron densities of those atoms or ions.
  • a B cell ligand may be coupled to a therapeutic agent as a fusion protein.
  • a therapeutic agent comprises a radioactive isotope such as an ⁇ -, ⁇ -, or ⁇ -emitter, or a ⁇ - and ⁇ -emitter.
  • a therapeutic agent comprises a chemotherapy.
  • Chemotherapeutic agents include, for example, including alkylating agents, anthracyclines, cytoskeletal disruptors (Taxanes), epothilones, histone deacetylase inhibitors, inhibitors of topoisomerase I, inhibitors of topoisomerase II, kinase inhibitors, nucleotide analogs and precursor analogs, peptide antibiotics, platinum-based agents, retinoids, vinca alkaloids and derivatives thereof.
  • Non-limiting examples include: (i) anti-angiogenic agents (e.g., TNP-470, platelet factor 4, thrombospondin-1, tissue inhibitors of metalloproteases (TIMP1 and TIMP2), prolactin (16-Kd fragment), angiostatin (38-Kd fragment of plasminogen), endostatin, bFGF soluble receptor, transforming growth factor beta, interferon alpha, soluble KDR and FLT-1 receptors, placental proliferin-related protein, as well as those listed by Carmeliet and Jain (2000)); (ii) a VEGF antagonist or a VEGF receptor antagonist such as anti-VEGF antibodies, VEGF variants, soluble VEGF receptor fragments, aptamers capable of blocking VEGF or VEGFR, neutralizing anti-VEGFR antibodies, inhibitors of VEGFR tyrosine kinases and any combinations thereof; and (iii) chemotherapeutic compounds such as, e.g., pyrim
  • a therapeutic agent comprises an immunotherapy.
  • Cancer immunotherapy is the use of the immune system to reject cancer.
  • the main premise is stimulating the subject's immune system to attack the tumor cells that are responsible for the disease. This can be either through immunization of the subject, in which case the subject's own immune system is rendered to recognize tumor cells as targets to be destroyed, or through the administration of therapeutics, such as antibodies, as drugs, in which case the subject's immune system is recruited to destroy tumor cells by the therapeutic agents.
  • Cancer immunotherapy includes an antibody-based therapy and cytokine-based therapy.
  • a number of therapeutic monoclonal antibodies have been approved by the FDA for use in humans, and more are underway.
  • the FDA-approved monoclonal antibodies for cancer immunotherapy include antibodies against CD52, CD33, CD20, ErbB2, vascular endothelial growth factor and epidermal growth factor receptor.
  • Examples of monoclonal antibodies approved by the FDA for cancer therapy include, without limitation: Rituximab (available as RituxanTM), Trastuzumab (available as HerceptinTM), Alemtuzumab (available as Campath-IHTM), Cetuximab (available as ErbituxTM), Bevacizumab (available as AvastinTM), Panitumumab (available as VectibixTM), Gemtuzumab ozogamicin (available as MylotargTM), Ibritumomab tiuxetan (available as ZevalinTM), Tositumomab (available as BexxarTM), Ipilimumab (available as YervoyTM), Ofatunumab (available as ArzerraTM), Daclizumab (available as ZinbrytaTM), Nivolumab (available as OpdivoTM), and Pembrolizumab (available as KeytrudaTM).
  • Rituximab available as RituxanTM
  • Examples of monoclonal antibodies currently undergoing human clinical testing for cancer therapy in the United States include, without limitation: WX-G250 (available as RencarexTM), Zanolimumab (available as HuMax-CD4), ch14.18, Zalutumumab (available as HuMax-EGFr), Oregovomab (available as B43.13, OvalRexTM), Edrecolomab (available as IGN-101, PanorexTM), 1311-chTNT-I/B (available as CotaraTM), Pemtumomab (available as R-1549, TheragynTM), Lintuzumab (available as SGN-33), Labetuzumab (available as hMN14, CEAcideTM), Catumaxomab (available as RemovabTM), CNTO 328 (available as cCLB8), 3F8, 177Lu-J591, Nimotuzumab, SGN-30, Ticilimumab (available as CP
  • Cancer immunotherapy also includes a cytokine-based therapy.
  • the cytokine-based cancer therapy utilizes one or more cytokines that modulate a subject's immune response.
  • cytokines useful in cancer treatment include interferon- ⁇ (IFN- ⁇ ), interleukin-2 (IL-2), Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12).
  • B cell receptor ligand coupled to therapeutic agents, as well as encoding nucleic acids or nucleic acid sets, vectors comprising such, or host cells comprising the vectors, described herein are useful for treating cancer, including B cell malignancies, e.g. B cell lymphomas.
  • more than one B cell receptor ligand coupled to a therapeutic agent may be administered to a subject in need of the treatment.
  • the B cell receptor ligand coupled to a therapeutic agent can also be used in conjunction with other agents that serve to enhance and/or complement the effectiveness of the agents.
  • kits for treatment comprises concomitantly administering CAR-expressing T-cells, wherein the CAR comprises an antigen binding domain that specifically binds a cancer-specific antigen in a cancer-specific manner; and a vaccine comprising a polypeptide or a nucleic acid expressing the cancer-specific antigen, or a cancer-specific fragment thereof.
  • the cancer-specific antigen comprises a B cell receptor and the antigen binding domain comprises a B cell receptor ligand described herein.
  • the antigen binding domain comprises a B cell receptor ligand described herein identified by the methods described herein.
  • cancer-specific antigen or “tumor antigen” interchangeably refers to a molecule (typically a protein, carbohydrate or lipid) that is expressed on the surface of a cancer cell, either entirely or as a fragment (e.g., MHC/peptide), and which is useful for the preferential targeting of a pharmacological agent to the cancer cell.
  • the cancer-specific antigen comprises a B cell receptor and the antigen binding domain comprises a B cell receptor ligand described herein.
  • the antigen binding domain comprises a B cell receptor ligand described herein identified by the methods described herein.
  • a tumor antigen is a marker expressed by both normal cells and cancer cells, e.g., a lineage marker, e.g., CD19 on B cells.
  • a tumor antigen is a cell surface molecule that is overexpressed in a cancer cell in comparison to a normal cell, for instance, 1-fold over expression, 2-fold overexpression, 3-fold overexpression or more in comparison to a normal cell.
  • a tumor antigen comprises a somatic mutation, e.g., is a cell surface molecule that is inappropriately synthesized in the cancer cell, for instance, a molecule that contains deletions, additions or mutations in comparison to the molecule expressed on a normal cell.
  • a cancer-specific antigen comprises a point mutation, a splice-site mutation, a frameshift mutation, a read-through mutation, or a gene-fusion mutation.
  • a cancer-specific antigen comprises a mutation in EGFRvIII, PSCA, BCMA, CD30, CEA, CD22, L1CAM, ROR1, ErbB, CD123, IL13R ⁇ 2, Mesothelin, FR ⁇ , VEGFR, c-Met, 5T4, CD44v6, B7-H4, CD133, CD138, CD33, CD28, GPC3, EphA2, CD19, ACVR2B, anaplastic lymphoma kinase (ALK), MYCN, BCR, HER2, NY-ESO1, MUC1, or MUC16.
  • a tumor antigen will be expressed exclusively on the cell surface of a cancer cell, entirely or as a fragment (e.g., MHC/peptide), and not synthesized or expressed on the
  • the cancer-specific antigen binds a cancer-specific antigen in a cancer-specific manner.
  • the cancer-specific antigen when a the cancer-specific antigen binds a cancer-specific antigen in a cancer-specific manner, the cancer-specific antigen binds cancerous cells with 1.1 ⁇ , 1.5 ⁇ , 2 ⁇ , 3 ⁇ , 4 ⁇ , 5 ⁇ , 6 ⁇ , 7 ⁇ , 8 ⁇ , 9 ⁇ , 10 ⁇ , 20 ⁇ , 30 ⁇ , 40 ⁇ , 50 ⁇ , 60 ⁇ , 70 ⁇ , 80 ⁇ , 90 ⁇ , 100 ⁇ , 200 ⁇ , 300 ⁇ , 400 ⁇ , 500 ⁇ , 600 ⁇ , 700 ⁇ , 800 ⁇ , 900 ⁇ , 1,000 ⁇ or more affinity than non-cancerous cells.
  • the methods described herein comprise identifying the cancer-specific antigen in a subject.
  • identifying the cancer-specific antigen comprises obtaining cancerous cells from a subject.
  • the cancerous cells are obtained from a biopsy.
  • the cancerous cells are in the blood of the subject.
  • DNA from the cancerous cells is extracted and sequenced.
  • sequence of the DNA, or of one or more genes is compared to the same sequence in non-cancerous cells.
  • RNA from the cancerous cells is extracted and cDNA is synthesized.
  • the cDNA is sequenced, In some embodiments, the sequence of the cDNA, or of one or more genes is compared to the same sequence in non-cancerous cells.
  • identifying the cancer-specific antigen comprises isolating and sequencing circulating cell free DNA of the subject.
  • Conscomitantly means administering two or more substances to a subject in a manner that is correlated in time, preferably sufficiently correlated in time so as to provide a modulation in an immune response.
  • concomitant administration may occur through administration of two or more substances in the same dosage form.
  • concomitant administration may encompass administration of two or more substances in different dosage forms, but within a specified period of time, preferably within 1 month, more preferably within 1 week, still more preferably within 1 day, and even more preferably within 1 hour.
  • the use of the term “concomitantly” does not restrict the order in which the therapeutic agents are administered to a subject.
  • a first therapeutic agent such as a CAR-T cell
  • can be administered prior to e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before
  • a second therapeutic agent such as a vaccine described herein
  • a first agent can be administered separately, sequentially or simultaneously with the second therapeutic agent.
  • the concomitant administration occurs at least two times, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, or at least ten times in the subject.
  • the CAR-expressing T cells are administered before the vaccine. In some embodiments, the CAR-expressing T cells are administered after the vaccine.
  • an effective amount of the B cell receptor ligand coupled to a therapeutic agent, the CARs, and the vaccines described herein can be administered to a subject (e.g., a human) in need of the treatment via a suitable route, such as intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, inhalation or topical routes.
  • a suitable route such as intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, inhalation or topical routes.
  • vaccines described herein are administered intratumorally.
  • CAR T-cells described herein are administered intraveneously.
  • nebulizers for liquid formulations, including jet nebulizers and ultrasonic nebulizers are useful for administration.
  • Liquid formulations can be directly nebulized and lyophilized powder can be nebulized after reconstitution.
  • the B cell receptor ligand coupled to a therapeutic agent, the CARs, and the vaccines as described herein can be aerosolized using a fluorocarbon formulation and a metered dose inhaler, or inhaled as a lyophilized and milled powder.
  • the subject to be treated by the methods described herein can be a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, horses, dogs, cats, mice and rats.
  • a human subject who needs the treatment may be a human patient having, at risk for, or suspected of having a target disease/disorder, such as cancer.
  • a subject having a target disease or disorder can be identified by routine medical examination, e.g., laboratory tests, organ functional tests, CT scans, or ultrasounds.
  • a subject suspected of having any of such target disease/disorder might show one or more symptoms of the disease/disorder.
  • a subject at risk for the disease/disorder can be a subject having one or more of the risk factors for that disease/disorder.
  • the cancer is a B cell malignancy.
  • the cancer is a lymphoma.
  • the cancer is selected from diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone B-cell lymphoma (MZL) or mucosa-associated lymphatic tissue lymphoma (MALT), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Burkitt's lymphoma, lymphoplasmacytic lymphoma, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, primary central nervous system lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B
  • cancers include but are not limited to: Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymph
  • an effective amount refers to the amount of each active agent required to confer therapeutic effect on the subject, either alone or in combination with one or more other active agents.
  • the therapeutic effect is reduction in progression of cancer. Determination of whether an amount of the B cell receptor ligand coupled to a therapeutic agent described herein, or the CARs and the vaccines described herein achieved the therapeutic effect would be evident to one of skill in the art. Effective amounts vary, as recognized by those skilled in the art, depending on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size, gender and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment.
  • Frequency of administration may be determined and adjusted over the course of therapy, and is generally, but not necessarily, based on treatment and/or suppression and/or amelioration and/or delay of a target disease/disorder.
  • dosages may be determined empirically in individuals who have been given one or more administration(s) of the molecule. Individuals are given incremental dosages of the molecule.
  • an indicator of the disease/disorder can be followed.
  • the appropriate dosage will depend on the type and severity of the disease/disorder, whether the B cell receptor ligand coupled to a therapeutic agent or the CARs and the vaccines described herein is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the B cell receptor ligand coupled to a therapeutic agent or the CARs and the vaccines, and the discretion of the attending physician.
  • the clinician will administer the B cell receptor ligand coupled to a therapeutic agent or the CARs and the vaccines, until a dosage is reached that achieves the desired result.
  • the desired result is a decrease the severity of cancer.
  • Administration of one or more B cell receptor ligands coupled to a therapeutic agents or the CARs and the vaccines can be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
  • the administration of a B cell receptor ligand coupled to a therapeutic agent or the CARs and the vaccines may be essentially continuous over a preselected period of time or may be in a series of spaced dose, e.g., either before, during, or after developing a target disease or disorder.
  • treating refers to the application or administration of a composition including one or more active agents to a subject, who has a target disease or disorder, a symptom of the disease/disorder, or a predisposition toward the disease/disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward the disease or disorder.
  • Alleviating a target disease/disorder includes delaying the development or progression of the disease, or reducing disease severity. Alleviating the disease does not necessarily require curative results. As used therein, “delaying” the development of a target disease or disorder means to defer, hinder, slow, retard, stabilize, and/or postpone progression of the disease. This delay can be of varying lengths of time, depending on the history of the disease and/or individuals being treated.
  • a method that “delays” or alleviates the development of a disease, or delays the onset of the disease is a method that reduces probability of developing one or more symptoms of the disease in a given time frame and/or reduces extent of the symptoms in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a number of subjects sufficient to give a statistically significant result.
  • “Development” or “progression” of a disease means initial manifestations and/or ensuing progression of the disease. Development of the disease can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development or progression refers to the biological course of the symptoms. “Development” includes occurrence, recurrence, and onset. As used herein “onset” or “occurrence” of a target disease or disorder includes initial onset and/or recurrence.
  • the B cell receptor ligand coupled to a therapeutic agent or the CARs and the vaccines described herein can be administered via conventional routes, e.g., administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.
  • injectable depot routes of administration such as using 1-, 3-, or 6-month depot injectable or biodegradable materials and methods.
  • the pharmaceutical composition is administered intraocularly or intravitreally.
  • the B cell receptor ligand coupled to a therapeutic agent or the CARs and the vaccines described herein is administered via site-specific or targeted local delivery techniques.
  • site-specific or targeted local delivery techniques include various implantable depot sources of the antibody or local delivery catheters, such as infusion catheters, an indwelling catheter, or a needle catheter, synthetic grafts, adventitial wraps, shunts and stents or other implantable devices, site specific carriers, direct injection, or direct application. See, e.g., PCT Publication No. WO 00/53211 and U.S. Pat. No. 5,981,568.
  • Targeted delivery of therapeutic compositions containing an antisense polynucleotide, expression vector, or subgenomic polynucleotides can also be used.
  • Receptor-mediated DNA delivery techniques are described in, for example, Findeis et al., Trends Biotechnol. (1993) 11:202; Chiou et al., Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (J. A. Wolff, ed.) (1994); Wu et al., J. Biol. Chem. (1988) 263:621; Wu et al., J. Biol. Chem. (1994) 269:542; Zenke et al., Proc. Natl. Acad. Sci. USA (1990) 87:3655; Wu et al., J. Biol. Chem. (1991) 266:338.
  • the therapeutic polynucleotides and polypeptides described herein can be delivered using gene delivery vehicles.
  • the gene delivery vehicle can be of viral or non-viral origin (see generally, Jolly, Cancer Gene Therapy (1994) 1:51; Kimura, Human Gene Therapy (1994) 5:845; Connelly, Human Gene Therapy (1995) 1:185; and Kaplitt, Nature Genetics (1994) 6:148).
  • Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters and/or enhancers. Expression of the coding sequence can be either constitutive or regulated.
  • Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art.
  • Exemplary viral-based vehicles include, but are not limited to, recombinant retroviruses (see, e.g., PCT Publication Nos. WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; WO 93/11230; WO 93/10218; WO 91/02805; U.S. Pat. Nos. 5,219,740 and 4,777,127; GB Patent No. 2,200,651; and EP Patent No.
  • alphavirus-based vectors e.g., Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR 1249; ATCC VR-532)
  • AAV adeno-associated virus
  • Non-viral delivery vehicles and methods can also be employed, including, but not limited to, polycationic condensed DNA linked or unlinked to killed adenovirus alone (see, e.g., Curiel, Hum. Gene Ther. (1992) 3:147); ligand-linked DNA (see, e.g., Wu, J. Biol. Chem. (1989) 264:16985); eukaryotic cell delivery vehicles cells (see, e.g., U.S. Pat. No. 5,814,482; PCT Publication Nos. WO 95/07994; WO 96/17072; WO 95/30763; and WO 97/42338) and nucleic charge neutralization or fusion with cell membranes. Naked DNA can also be employed.
  • Exemplary naked DNA introduction methods are described in PCT Publication No. WO 90/11092 and U.S. Pat. No. 5,580,859.
  • Liposomes that can act as gene delivery vehicles are described in U.S. Pat. No. 5,422,120; PCT Publication Nos. WO 95/13796; WO 94/23697; WO 91/14445; and EP Patent No. 0524968. Additional approaches are described in Philip, Mol. Cell. Biol. (1994) 14:2411, and in Woffendin, Proc. Natl. Acad. Sci. (1994) 91:1581.
  • the particular dosage regimen i.e., dose, timing and repetition, used in the method described herein will depend on the particular subject and that subject's medical history.
  • Treatment efficacy for a target disease/disorder can be assessed by methods well-known in the art.
  • the term “in combination” refers to the use of more than one therapeutic agent.
  • the use of the term “in combination” does not restrict the order in which the therapeutic agents are administered to a subject.
  • a first therapeutic agent can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapeutic agent.
  • a first agent can be administered separately, sequentially or simultaneously with the second therapeutic agent.
  • a CAR-T cell and a vaccine described herein are administered in combination with a TLR9 agonist.
  • the TLR9 agonist is a CpG oligonucleotide.
  • CAR-expressing T-cells described herein are administered with a vaccine.
  • the vaccine comprises a polypeptide or a nucleic acid expressing a cancer-specific antigen, or a cancer-specific fragment thereof, as is described supra.
  • the vaccine comprises a cancer-specific fragment of a cancer-specific antigen.
  • the cancer-specific fragment of the cancer specific antigen is 1-1000 amino acids long, or 10-500 amino acids long. In some embodiments, the cancer-specific fragment of the cancer specific antigen is 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, or 500 or more amino acids long.
  • the cancer-specific antigen, or a cancer-specific fragment thereof comprises a somatic mutation as is described supra, e.g., comprises a point mutation, a splice-site mutation, a frameshift mutation, a read-through mutation, or a gene-fusion mutation, and the polypeptide or nucleic acid expressing the cancer-specific antigen, or cancer-specific fragment thereof comprises the somatic mutation.
  • the vaccine comprises a polypeptide expressing a cancer-specific antigen, or a cancer-specific fragment thereof.
  • the DNA that encodes for the protein vaccine can be introduced into an expression vector, such as a plasmid. Multiple cloning sites, which contain DNA sequences that are recognized by restriction enzymes, can facilitate the insertion of the protein vaccine DNA into the vector.
  • DNA constructs (such as expression vectors) that encode the proteins of interest can be introduced into cells to induce protein expression and the cells can be harvested to extract the protein of interest.
  • the DNA encoding the protein of interest can be included in an expression vector that also contains sequences that control gene expression, such as promoter sequences. 5′ and 3′ untranslated regions can be encoded upstream and downstream of the protein coding sequence in order to enhance expression.
  • a 5′ untranslated leader sequence and a 3′ polyadenylation sequence can be used.
  • the DNA can be introduced into cells for protein expression by heat-shock transformation.
  • DNA can be introduced into cells for protein expression by transfection, electroporation, impalefection or hydrodynamic delivery.
  • the DNA used for protein expression can be delivered in the form of a viral vector.
  • the protein of interest can be harvested from lysed cells, and purified. Protein purification can be performed using size-exclusion chromatography, or by a chromatography technique that isolates the protein based on a protein-tag, such as a 6 ⁇ histidine tag or a c-myc tag.
  • the histidine tag can be encoded adjacent to a sequence recognized and cleaved by a protease, to facilitate removal of the histidine tag after protein purification.
  • a protease that can be used to remove a histidine tag from a protein is the human rhinovirus 3C protease.
  • the vaccine comprises two or more polypeptides having overlapping sequences, each expressing a fragment of the cancer-specific antigen.
  • the polypeptide is conjugated to a carrier protein, e.g., OVA, KLH, or BSA.
  • a carrier protein e.g., OVA, KLH, or BSA.
  • the vaccine comprises a nucleic acid expressing a cancer-specific antigen, or a cancer-specific fragment thereof.
  • the nucleic acid is DNA.
  • a DNA vaccine may comprise an “expression vector” or “expression cassette,” i.e., a nucleotide sequence which is capable of affecting expression of a protein coding sequence in a host compatible with such sequences.
  • Expression cassettes include at least a promoter operably linked with the polypeptide coding sequence; and, optionally, with other sequences, e.g., transcription termination signals. Additional factors necessary or helpful in effecting expression may also be included, e.g., enhancers.
  • “Operably linked” means that the coding sequence is linked to a regulatory sequence in a manner that allows expression of the coding sequence.
  • Known regulatory sequences are selected to direct expression of the desired protein in an appropriate host cell. Accordingly, the term “regulatory sequence” includes promoters, enhancers and other expression control elements. Such regulatory sequences are described in, for example, Goeddel, Gene Expression Technology. Methods in Enzymology , vol. 185, Academic Press, San Diego, Calif. (1990)).
  • a promoter region of a DNA or RNA molecule binds RNA polymerase and promotes the transcription of an “operably linked” nucleic acid sequence.
  • a “promoter sequence” is the nucleotide sequence of the promoter which is found on that strand of the DNA or RNA which is transcribed by the RNA polymerase.
  • Two sequences of a nucleic acid molecule, such as a promoter and a coding sequence are “operably linked” when they are linked to each other in a manner which permits both sequences to be transcribed onto the same RNA transcript or permits an RNA transcript begun in one sequence to be extended into the second sequence.
  • two sequences such as a promoter sequence and a coding sequence of DNA or RNA are operably linked if transcription commencing in the promoter sequence will produce an RNA transcript of the operably linked coding sequence.
  • a promoter sequence and a coding sequence of DNA or RNA are operably linked if transcription commencing in the promoter sequence will produce an RNA transcript of the operably linked coding sequence.
  • two sequences In order to be “operably linked” it is not necessary that two sequences be immediately adjacent to one another in the linear sequence.
  • the preferred promoter sequences of the present invention must be operable in mammalian cells and may be either eukaryotic or viral promoters. Suitable promoters may be inducible, repressible or constitutive.
  • a “constitutive” promoter is one which is active under most conditions encountered in the cell's environmental and throughout development.
  • An “inducible” promoter is one which is under environmental or developmental regulation.
  • a “tissue specific” promoter is active in certain tissue types of an organism.
  • An example of a constitutive promoter is the viral promoter MSV-LTR, which is efficient and active in a variety of cell types, and, in contrast to most other promoters, has the same enhancing activity in arrested and growing cells.
  • CMV-LTR from cytomegalovirus
  • RSV-LTR from Rous sarcoma virus
  • promoter of the mouse metallothionein I gene Hamer, D, et al., J. Mol. Appl. Gen.
  • transcriptional factor association with promoter regions and the separate activation and DNA binding of transcription factors include: Keegan et al., Nature 231:699, 1986; Fields et al., Nature 340:245, 1989 ; Jones, Cell 61:9, 1990; Lewin, Cell 61:1161, 1990; Ptashne et al., Nature 346:329, 1990; Adams et al., Cell 72:306, 1993.
  • the promoter region may further include an octamer region which may also function as a tissue specific enhancer, by interacting with certain proteins found in the specific tissue.
  • the enhancer domain of the DNA construct of the present invention is one which is specific for the target cells to be transfected, or is highly activated by cellular factors of such target cells. Examples of vectors (plasmid or retrovirus) are disclosed, e.g., in Roy-Burman et al., U.S. Pat. No. 5,112,767. For a general discussion of enhancers and their actions in transcription, see, Lewin, B M, Genes IV , Oxford University Press pp. 552-576, 1990 (or later edition).
  • retroviral enhancers e.g., viral LTR
  • the endogenous viral LTR may be rendered enhancer-less and substituted with other desired enhancer sequences which confer tissue specificity or other desirable properties such as transcriptional efficiency.
  • expression cassettes include plasmids, recombinant viruses, any form of a recombinant “naked DNA” vector, and the like.
  • a “vector” comprises a nucleic acid which can infect, transfect, transiently or permanently transduce a cell. It will be recognized that a vector can be a naked nucleic acid, or a nucleic acid complexed with protein or lipid.
  • the vector optionally comprises viral or bacterial nucleic acids and/or proteins, and/or membranes (e.g., a cell membrane, a viral lipid envelope, etc.).
  • Vectors include replicons (e.g., RNA replicons), bacteriophages) to which fragments of DNA may be attached and become replicated.
  • Vectors thus include, but are not limited to RNA, autonomous self-replicating circular or linear DNA or RNA, e.g., plasmids, viruses, and the like (U.S. Pat. No. 5,217,879), and includes both the expression and nonexpression plasmids.
  • a recombinant cell or culture is described as hosting an “expression vector” this includes both extrachromosomal circular and linear DNA and DNA that has been incorporated into the host chromosome(s).
  • the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incorporated within the host's genome.
  • virus vectors that may be used include recombinant adenoviruses (Horowitz, M S, In: Virology , Fields, B N et al., eds, Raven Press, N Y, 1990, p. 1679; Berkner, K L, Biotechniques 6:616-29, 1988; Strauss, S E, In: The Adenoviruses, Ginsberg, H S, ed., Plenum Press, N Y, 1984, chapter 11) and herpes simplex virus (HSV).
  • HSV herpes simplex virus
  • adenovirus vectors for human gene delivery include the fact that recombination is rare, no human malignancies are known to be associated with such viruses, the adenovirus genome is double stranded DNA which can be manipulated to accept foreign genes of up to 7.5 kb in size, and live adenovirus is a safe human vaccine organisms.
  • Adeno-associated virus is also useful for human therapy (Samulski, R J et al., EMBO J. 10:3941, 1991) according to the present invention.
  • vaccinia virus which can be rendered non-replicating (U.S. Pat. Nos. 5,225,336; 5,204,243; 5,155,020; 4,769,330; Fuerst, T R et al., Proc. Natl. Acad. Sci. USA 86:2549-53, 1992; Chakrabarti, S et al., Mol Cell Biol 5:3403-9, 1985).
  • viral vectors that may be used include viral or non-viral vectors, including adeno-associated virus vectors, retrovirus vectors, lentivirus vectors, and plasmid vectors.
  • exemplary types of viruses include HSV (herpes simplex virus), AAV (adeno associated virus), HIV (human immunodeficiency virus), BIV (bovine immunodeficiency virus), and MLV (murine leukemia virus).
  • a DNA vaccine may also use a replicon, e.g., an RNA replicon, a self-replicating RNA vector.
  • RNA replicon vaccines may be derived from alphavirus vectors, such as Sindbis virus (Hariharan, M J et al., 1998. J Virol 72:950-8.), Semliki Forest virus (Berglund, P M et al., 1997. AIDS Res Hum Retroviruses 13:1487-95; Ying, H T et al., 1999. Nat Med 5:823-77) or Venezuelan equine encephalitis virus (Pushko, P M et al., 1997. Virology 239:389-401).
  • RNA or (2) DNA which is then transcribed into RNA replicons in cells transfected in vitro or in vivo (Berglund, P C et al., 1998. Nat Biotechnol 16:562-5; Leitner, W W et al., 2000. Cancer Res 60:51-5).
  • An exemplary Semliki Forest virus is pSCAI (DiCiommo, D P et al., J Biol Chem 1998; 273:18060-6).
  • engineered bacteria may be used as vectors.
  • a number of bacterial strains including Salmonella , BCG and Listeria monocytogenes (LM) (Hoiseth et al., Nature 291:238-9, 1981; Poirier, T P et al., J Exp Med 168:25-32, 1988); Sadoff, J C et al., Science 240:336-8, 1988; Stover, C K et al., Nature 351:456-60, 1991; Aldovini, A et al., Nature 351:479-82, 1991).
  • LM Listeria monocytogenes
  • electroporation a well-known means to transfer genes into cell in vitro, can be used to transfer DNA molecules according to the present invention to tissues in vivo (Titomirov, A V et al., Biochim Biophys Acta 1088:131, 1991).
  • Carrier mediated gene transfer has also been described (Wu, C H et al., J Biol Chem 264:16985, 1989; Wu, G Y et al., J Biol Chem 263:14621, 1988; Soriano, P et al., Proc Nat. Acad Sci USA 80:7128, 1983; Wang, C-Y et al., Pro. Natl Acad Sci USA 84:7851, 1982; Wilson, J M et al., J Biol Chem 267:963, 1992).
  • Preferred carriers are targeted liposomes (Nicolau, C et al., Proc Natl Acad Sci USA 80:1068, 1983; Soriano et al., supra) such as immunoliposomes, which can incorporate acylated mAbs into the lipid bilayer (Wang et al., supra).
  • Polycations such as asialoglycoprotein/polylysine (Wu et al., 1989, supra) may be used, where the conjugate includes a target tissue-recognizing molecule (e.g., asialo-orosomucoid for liver) and a DNA binding compound to bind to the DNA to be transfected without causing damage, such as polylysine. This conjugate is then complexed with plasmid DNA of the present invention.
  • a target tissue-recognizing molecule e.g., asialo-orosomucoid for liver
  • DNA binding compound to bind to the DNA to be transfected without causing damage, such as poly
  • Plasmid DNA used for transfection or microinjection may be prepared using methods well-known in the art, for example using the Qiagen procedure (Qiagen), followed by DNA purification using known methods, such as the methods exemplified herein.
  • Such expression vectors may be used to transfect host cells (in vitro, ex vivo or in vivo) for expression of the DNA and production of the encoded proteins which include fusion proteins or peptides.
  • a DNA vaccine is administered to or contacted with a cell, e.g., a cell obtained from a subject (e.g., an antigen presenting cell), and administered to a subject, wherein the subject is treated before, after or at the same time as the cells are administered to the subject.
  • the vaccine comprises a nucleic acid expressing a cancer-specific antigen, or a cancer-specific fragment thereof, and the nucleic acid is RNA.
  • RNA vaccines comprise at least one (one or more) ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one cancer-specific antigen, or a cancer-specific fragment thereof.
  • RNA ribonucleic acid
  • polynucleotides of the present disclosure function as messenger RNA (mRNA).
  • mRNA messenger RNA
  • “Messenger RNA” (mRNA) refers to any polynucleotide that encodes a (at least one) polypeptide (a naturally-occurring, non-naturally-occurring, or modified polymer of amino acids) and can be translated to produce the encoded polypeptide in vitro, in vivo, in situ or ex vivo.
  • the basic components of an mRNA molecule typically include at least one coding region, a 5′ untranslated region (UTR), a 3′ UTR, a 5′ cap and a poly-A tail.
  • Polynucleotides of the present disclosure may function as mRNA but can be distinguished from wild-type mRNA in their functional and/or structural design features which serve to overcome existing problems of effective polypeptide expression using nucleic-acid based therapeutics.
  • RNA vaccines of the present disclosure comprise, in some embodiments, at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one a cancer-specific antigen, or a cancer-specific fragment thereof, wherein said RNA comprises at least one chemical modification.
  • RNA ribonucleic acid
  • Polynucleotides e.g., RNA polynucleotides, such as mRNA polynucleotides
  • RNA polynucleotides such as mRNA polynucleotides
  • a particular region of a polynucleotide contains one, two or more (optionally different) nucleoside or nucleotide modifications.
  • a modified RNA polynucleotide e.g., a modified mRNA polynucleotide
  • introduced to a cell or organism exhibits reduced degradation in the cell or organism, respectively, relative to an unmodified polynucleotide.
  • a modified RNA polynucleotide e.g., a modified mRNA polynucleotide
  • introduced into a cell or organism may exhibit reduced immunogenicity in the cell or organism, respectively (e.g., a reduced innate response).
  • Polynucleotides e.g., RNA polynucleotides, such as mRNA polynucleotides
  • RNA polynucleotides such as mRNA polynucleotides
  • polynucleotides in some embodiments, comprise non-natural modified nucleotides that are introduced during synthesis or post-synthesis of the polynucleotides to achieve desired functions or properties.
  • the modifications may be present on an internucleotide linkages, purine or pyrimidine bases, or sugars.
  • the modification may be introduced with chemical synthesis or with a polymerase enzyme at the terminal of a chain or anywhere else in the chain. Any of the regions of a polynucleotide may be chemically modified.
  • nucleosides and nucleotides of a polynucleotide e.g., RNA polynucleotides, such as mRNA polynucleotides.
  • a “nucleoside” refers to a compound containing a sugar molecule (e.g., a pentose or ribose) or a derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to herein as “nucleobase”).
  • a nucleotide refers to a nucleoside, including a phosphate group.
  • Modified nucleotides may by synthesized by any useful method, such as, for example, chemically, enzymatically, or recombinantly, to include one or more modified or non-natural nucleosides.
  • Polynucleotides may comprise a region or regions of linked nucleosides. Such regions may have variable backbone linkages. The linkages may be standard phosphdioester linkages, in which case the polynucleotides would comprise regions of nucleotides.
  • Cancer vaccines of the present disclosure comprise at least one RNA polynucleotide, such as a mRNA (e.g., modified mRNA).
  • mRNA for example, is transcribed in vitro from template DNA, referred to as an “in vitro transcription template.”
  • an in vitro transcription template encodes a 5′ untranslated (UTR) region, contains an open reading frame, and encodes a 3′ UTR and a polyA tail.
  • UTR untranslated
  • a polynucleotide includes 200 to 3,000 nucleotides.
  • a polynucleotide may include 200 to 500, 200 to 1000, 200 to 1500, 200 to 3000, 500 to 1000, 500 to 1500, 500 to 2000, 500 to 3000, 1000 to 1500, 1000 to 2000, 1000 to 3000, 1500 to 3000, or 2000 to 3000 nucleotides).
  • the invention relates to a method for preparing an mRNA cancer vaccine by IVT methods.
  • IVT In vitro transcription
  • IVT methods permit template-directed synthesis of RNA molecules of almost any sequence.
  • the size of the RNA molecules that can be synthesized using IVT methods range from short oligonucleotides to long nucleic acid polymers of several thousand bases.
  • IVT methods permit synthesis of large quantities of RNA transcript (e.g., from microgram to milligram quantities) (Beckert et al., Synthesis of RNA by in vitro transcription, Methods Mol Biol. 703:29-41(2011); Rio et al. RNA: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 2011, 205-220.; Cooper, Geoffery M.
  • IVT utilizes a DNA template featuring a promoter sequence upstream of a sequence of interest.
  • the promoter sequence is most commonly of bacteriophage origin (ex. the T7, T3 or SP6 promoter sequence) but many other promotor sequences can be tolerated including those designed de novo.
  • Transcription of the DNA template is typically best achieved by using the RNA polymerase corresponding to the specific bacteriophage promoter sequence.
  • Exemplary RNA polymerases include, but are not limited to T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase, among others.
  • IVT is generally initiated at a dsDNA but can proceed on a single strand.
  • the vaccine minimally includes the antigen.
  • materials and methods can be employed to enhance availability of the vaccine.
  • One such method employs an adjuvant.
  • adjuvant refers to material that enhances the immune response to an antigen and is used herein in the customary use of the term. The precise mode of action is not understood for all adjuvants, but such lack of understanding does not prevent their clinical use for a wide variety of vaccines, whether protein-based or DNA-based. Traditionally, some adjuvants physically trap antigen at the site of injection, enhancing antigen presence at the site and slowing its release. This in turn prolongs and/or increases the recruitment and activation of APCs, such as in this case iDCs.
  • a squalene-based adjuvant is used.
  • Squalene is part of the group of molecules known as triterpenes, which are all hydrocarbons with 30 carbon molecules. Squalene can be derived from certain plant sources, such as rice bran, wheat germ, amaranth seeds, and olives, as well as from animal sources, such as shark liver oil.
  • the squalene-based adjuvant is MF59®, which is an oil-in-water emulsion (Novartis, Basel, Switzerland; see Giudice, G D et al. Clin Vaccine Immunol. 2006 September; 13(9): 1010-3).
  • squalene-based adjuvants can include 0.1%-20% (v/v) squalene oil.
  • squalene-based adjuvants can include 5% (v/v) squalene oil.
  • the squalene-based adjuvant is AS03, which includes ⁇ -tocopherol, squalene, and polysorbate 80 in an oil-in-water emulsion (GlaxoSmithKline; see Garcon N et al. Expert Rev Vaccines. 2012 March; 11(3):349-66).
  • polyinosinic:polycytidilyic acid also referred to as poly(I:C) is used.
  • Poly(I:C) is a synthetic analog of double-stranded RNA that stimulates the immune system.
  • Poly-ICLC Hammi R et al. Pharmacol Ther. 2015 February; 146:120-31).
  • Poliu-IC12U Ampligen is used (Martins K A et al. Expert Rev Vaccines. 2015 March; 14(3):447-59).
  • the adjuvant alum can be used.
  • Alum refers to a family of salts that contain two sulfate groups, a monovalent cation, and a trivalent metal, such as aluminum or chromium.
  • Alum is an FDA approved adjuvant.
  • vaccines can include alum in the amounts of 1-1000 ug/dose or 0.1 mg-10 mg/dose.
  • the adjuvant Vaxfectin® (Vical, Inc., San Diego, Calif.) can be used.
  • Vaxfectin® is a cationic lipid based adjuvant that can be used for DNA or protein vaccines.
  • compositions for Administration can be formulated into pharmaceutical compositions for administration including a vaccine of the disclosure can be formulated in a variety of forms, e.g., as a liquid, gel, lyophilized, or as a compressed solid. The particular form will depend upon the particular indication being treated and will be apparent to one of ordinary skill in the art.
  • compositions designed for parenteral administration.
  • parenteral formulations can also be provided in frozen or in lyophilized form.
  • the composition must be thawed prior to use.
  • the latter form is often used to enhance the stability of the active compound contained in the composition under a wider variety of storage conditions, as it is recognized by those or ordinary skill in the art that lyophilized preparations are generally more stable than their liquid counterparts.
  • Such lyophilized preparations are reconstituted prior to use by the addition of one or more suitable pharmaceutically acceptable diluents such as sterile water for injection or sterile physiological saline solution.
  • Parenterals can be prepared for storage as lyophilized formulations or aqueous solutions by mixing, as appropriate, the composition having the desired degree of purity with one or more pharmaceutically acceptable carriers, excipients or stabilizers typically employed in the art (all of which are termed “excipients”), for example buffering agents, stabilizing agents, preservatives, isotonifiers, non-ionic detergents, antioxidants and/or other miscellaneous additives.
  • excipients typically employed in the art
  • Buffering agents help to maintain the pH in the range which approximates physiological conditions. They are typically present at a concentration ranging from 2 mM to 50 mM.
  • Suitable buffering agents for use with the present disclosure include both organic and inorganic acids and salts thereof such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-d
  • Preservatives can be added to retard microbial growth, and are typically added in amounts of 0.2%-1% (w/v).
  • Suitable exemplary preservatives for use with the present disclosure include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides (e.g., benzalkonium chloride, bromide or iodide), hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol and 3-pentanol.
  • Isotonicifiers can be added to ensure isotonicity of liquid compositions and include polyhydric sugar alcohols, trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol.
  • Polyhydric alcohols can be present in an amount between 0.1% and 25% by weight, typically 1% to 5%, taking into account the relative amounts of the other ingredients.
  • Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the vaccine or helps to prevent denaturation or adherence to the container wall.
  • Typical stabilizers can be polyhydric sugar alcohols (enumerated above); amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc., organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, and glycerol; polyethylene glycol; amino acid polymers; sulfur-containing reducing agents, such as urea, glutathione, thioctic acid, sodium thio
  • Stabilizers are typically present in the range of from 0.1 to 10,000 parts by weight based on the vaccine composition. Additional miscellaneous excipients include bulking agents or fillers (e.g., starch), chelating agents (e.g., EDTA), antioxidants (e.g., ascorbic acid, methionine, vitamin E) and cosolvents.
  • bulking agents or fillers e.g., starch
  • chelating agents e.g., EDTA
  • antioxidants e.g., ascorbic acid, methionine, vitamin E
  • cosolvents e.g., ascorbic acid, methionine, vitamin E
  • the vaccine composition can also be entrapped in microcapsules prepared, for example, by coascervation techniques or by interfacial polymerization, for example hydroxymethylcellulose, gelatin or poly-(methylmethacylate) microcapsules, in colloidal drug delivery systems (for example liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • macroemulsions for example liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • Parenteral formulations to be used for in vivo administration generally are sterile. This is readily accomplished, for example, by filtration through sterile filtration membranes.
  • sustained-release vaccine compositions include semi-permeable matrices of solid hydrophobic polymers containing the composition, the matrices having a suitable form such as a film or microcapsules.
  • sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate) or poly(vinylalcohol)), polylactides, copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the PROLEASE® (Alkermes, Inc., Waltham, Mass.) technology or LUPRON DEPOT® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate; Abbott Endocrine, Inc., Abbott Park, Ill.), and poly-D-( ⁇ )-3-hydroxybutyric acid. While polymers such
  • lymphoma is a clonal malignancy of a diversity system, every tumor has a different antibody on its cell surface.
  • Combinatorial autocrine-based selection is used to rapidly identify specific ligands for these B cell receptors on the surface of FL tumor cells.
  • the selected ligands are used in a CAR-T format for redirection of human CTLs.
  • the format is the inverse of the usual CAR-T protocol.
  • the antibody itself is the target.
  • the B cell receptor (BCR) on lymphoma cells is the purest form of a tumor specific antigen (1).
  • lymphoma is a tumor of one member of a diversity system were each tumor expresses only one of 10 8 different antibody molecules (2).
  • antigens selective for BCR's binding have not been more generally used for therapy (3, 4).
  • the workflow to find a selective antigen for each patient is not possible in most therapeutic settings.
  • an autocrine-based format that allows identification of peptide antigens selective for individual BCR's with a speed compatible with their use in the clinic.
  • These selected antigens can be used as guide molecules for CAR-T or other approaches such as radiotherapy.
  • the main point is that autocrine-based selections allow for the speed and specificity that are required if personalized therapy of lymphoma is to be realized.
  • Lymph nodes biopsies from patients with follicular lymphoma diagnosis were kindly provided by N.N. Petrov Research Institute of Oncology (St. Russia). Immediately after surgery the biopsy sample was separated to four equal slices, two of them were loaded into the RNAlater reagent (Qiagen) and others were cryopreserved. Lymphoma cell counts and expression of surface Ig is determined by flow cytometry. Cell suspension aliquots containing approx. 250,000 cells were stained with monoclonal antibodies in 4 tubes: 1. Isotype control; 2. CD45-FITC, CD20-PE, CD3-PC5, CD19-PE-Cy7; 3.
  • RNAlater processed biopsy samples were used for isolation of the total mRNA using RNAeasy Mini Kit (Qiagen).
  • Total cDNA was synthesized by reverse transcription using a QuantiTect Reverse Transcription Kit (Qiagen).
  • Variable region genes of heavy and light Ig chains identified by flow cytometry were amplified in separate reactions for each gene.
  • Semi-nested PCR using high-fidelity DNA-polymerase (Q5, NEB) with a set of family specific V-gene forward primers and a C-gene specific reverse primer was used (Table 1).
  • First step PCR products were subjected to heteroduplex analysis in polyacrylamide gel to discriminate homoduplexes (monoclonal PCR products) from a smear of slowly moving heteroduplexes (derived from polyclonal lymphocytes). DNA fragments of the expected size are extracted and the DNA eluted.
  • Proximal reverse C-gene specific primer was used for the second step amplification and sequencing.
  • Identified variable fragments of the follicular lymphoma BCRs were cloned as a scFv into the lentiviral vector pLV2-Fc-MTA coding for a membrane-anchored human antibody Fc fragment (5) ( FIGS. 5B and 5C ) (FL).
  • Jurkat and Raji cells were transduced with these viruses.
  • Transduced Jurkat-FL and Raji-FL were analyzed by FACS in order to select the cells carrying the follicular lymphoma BCR, which were then used for autocrine selections or animal experiments.
  • the DNA fragment coding for the 3rd generation chimeric antigen T-cell receptor was synthesized (GeneCust) and cloned into the pLV2 lentiviral vector (Clontech) under control of the EF1a promoter.
  • the arrangement of genes are in the order of: interleukin 2 signal peptide at the N terminus; IgG1 Fc spacer domain with modified PELLGG and ISR motifs; GGGS linker; a CD28 trans-membrane and intracellular region; intracellular domains of the OX-40 and CD3zetta ( FIGS. 5A and 5C ).
  • the lentiviral library of CX 7 C-Fc-CAR was prepared by co-transfection of HEK293T cells with the library plasmid and the packaging plasmids. Supernatants containing virus were collected at 48 h post transfection. The titer of lentivirus preparations was determined using Lenti-X p24 ELISAs (Clontech).
  • Jurkat-FL1, Jurkat-FL2 and Jurkat-FL3 cells were transduced with the lentiviral cyclopeptide-CAR library.
  • CD69-positive cells were sorted using a FACSAria III (BD Biosciences).
  • the peptides sequences were determined directly from sorted cells by PCR of the genes that encode them and were cloned into the lentiviral vector to construct libraries for the next round of selection. Four iterative rounds of selection were carried out.
  • PBMCs Human peripheral blood mononuclear cells
  • CD8 Positive Isolation Kit (Life Technologies) was utilized for isolation of CD8 T cells from human PBMCs.
  • Human CD8 T cells were activated with CD3/CD28 beads at a 1:1 ratio (Life Technologies) in a complete RPMI media containing 40 IU/ml recombinant IL-2 for 72 hours.
  • Activated T cells were re-suspended at concentration of 4 million cells per 3 ml of FL1-CAR, FL2-CAR, FL3-CAR, CD19-CAR or Myc-Fc-CAR in lentiviral supernatant plus 1 ml of fresh RPMI media with 40 IU/ml IL-2 and cultured in 6-well plates. Plates were centrifuged at 1200 ⁇ g for 90 minutes at 32° C. and then incubated for 4 hours at 37° C. Second and third transductions were performed two more times.
  • mice were randomly assigned to experimental or control groups.
  • Tumor-bearing mice were injected intravenously (i.v.) with 3 ⁇ 10 6 FL1-CART, CD19-CART or Myc-CART cells on day 17 th post tumor inoculation. Tumor volume was measured with calipers and estimated using the ellipsoidal formula. Animals were sacrificed when the volume of the tumor node reached 2 cm 3 . On the 38th day after tumor inoculation (21st day post CART infusion), animals from each experimental group were used for isolation of blood, spleen and bone marrow cells.
  • Erythrocytes were lysed with RBC lysis buffer (0.15 M NH 4 Cl, 10 mM NaHCO 3 , 0.1 mM EDTA) and cells were stained with antibodies specific for CD3 (for blood samples), CD45RA and CCR7 and analyzed by Novocyte flow cytometer (ACEA Biosciences). The tumors were fixed in 4% neutral buffered formaldehyde for 2 weeks and processed for paraffin sectioning utilizing standard protocols.
  • a macroscopic post-mortem analysis included examination of the external surfaces, appearance of primary tumor nodes, thoracic condition, abdominal and pelvic cavities with their associated organs and tissues.
  • specimens of tumor nodes from each animal were collected during autopsy and fixed in 10% neutral-buffered formalin, dehydrated in ascending ethanols and xylols, and embedded in HISTOMIX paraffin (BioVitrum). Paraffin sections (5 Lm) were stained with hematoxylin and eosin, microscopically examined and scanned.
  • Tumor sections for immunohistochemical (IHC) studies (3-4 m) were sliced on a Microm HM 355S microtome (Thermo Fisher Scientific), and further de-paraffinated and rehydrated; antigen retrieval was carried out after exposure in a microwave oven at 700 W.
  • the samples were incubated with the CD8-specific antibodies (M3164, Spring BioScience) according to the manufacture's protocol.
  • the sections were incubated with secondary HRP-conjugated antibodies (Spring Bioscience detection system), exposed to DAB substrate, and stained with Mayer's hematoxylin.
  • Gross examination of tumors included evaluation of size of the tumor node, presence of a capsule, and presence of necrosis and hemorrhages.
  • Microscopic examination of tumors included evaluation of histopathological changes in tumor tissue in terms of necrosis and apoptosis, presence of mitoses and presence of CD8-lymphocyte infiltration.
  • the data obtained ex vivo were statistically processed using the Student's t-test (two-tailed, unpaired).
  • the tumor volume measurements were statistically processed using one-way ANOVA (STATISTICA 10.0). Survival curves were generated using the Kaplan-Meier method, and statistical comparisons were performed using the log-rank (Mantel-Cox) test. Significance was considered for p ⁇ 0.05.
  • cytotoxicity and specificity of engineered T cells were evaluated in a standard lactate dehydrogenase (LDH) release assay (CytoTox 96® Non-Radioactive Cytotoxicity Assay, Promega) following manufacturer's recommendations. Mock transduced, CD19-CAR, FL1-CAR, FL2-CAR, FL3-CAR, or Myc-CAR T cells were co-incubated for 6 hours together with 10 4 of the Raji-FL1, Raji-FL2, Raji-FL3 or cells from the patient's biopsy in a complete RPMI media supplemented with 40 U/ml of human IL-2. As negative controls Raji cells or cells isolated from an irrelevant lymphoma lymph node biopsy were used. All the experiments were performed in triplicate.
  • LDH lactate dehydrogenase
  • the following antibodies were used in this study; anti-human CD3 FITC (Biolegend), anti-human CD8 PE (Biolegend), anti-human CCR7 PE (Biolegend), anti-human CD45RA FITC (Biolegend), mouse anti-human CD69 Alexa Fluor488 (Biolegend), anti-human B220 APC (Biolegend).
  • Chimeric FL-BCR expression was detected using anti-human IgG1 PE antibody (SouthernBiotech) or synthetic biotinylated cyclopeptides (GeneCust) and streptavidin conjugated with FITC or PE (Thermo Fisher Scientific).
  • the CAR molecules were detected using goat cross-absorbed anti-human IgG antibody conjugated with DyLight650 (Thermo Fisher Scientific).
  • the CD19-CAR (FMC63 clone) molecules were detected using biotinylated protein L (Thermo Fisher Scientific) and streptavidin conjugated with FITC (Thermo Fisher Scientific).
  • Crude DNA extracts were prepared by proteinase K digestion of follicular lymphoma lymph node biopsy sample. PCR amplification was carried out using primer pairs comprising a consensus primer to JH and one of the three different primers homological to sequences in the mbr1, mcr2 or icr5 regions of bcl2 gene as described in (14).
  • lymphoma BCR Self-reactivity of the lymphoma BCR was tested by indirect immunofluorescence assay (IFA) on HEp-2 and HEL293T cells as described in (15). Plasmid vector encoding recombinant myoferlin (22443, Addgene) was transfected into the HEK293T cells with Lipofectamine 2000 (Invitrogen) as per the manufacturer's instructions. Recombinant Igs representing lymphoma BCR and irrelevant human antibody were diluted in PBS with 2% BSA and used at a concentration of 50 ⁇ g/mL and incubated with cells for 1 hour. Detection of bound antibodies were accomplished by anti-human Ig-PE using Nikon Eclipse Ti U microscope.
  • IFA indirect immunofluorescence assay
  • the aim of these proof-of-concept experiments is to find an antigen that selectively reacts with the BCR on the surface of the lymphoma cell ( FIG. 1 ).
  • the central idea is that if the BCR can be cloned and expressed on the surface of indicator cells also expressing a very large array of peptides, the system becomes autocrine and each cell becomes a selection system onto itself. If the overall system is constructed such that the BCR signals when it reacts with one of the co-expressed ligands, specific interactions between the BCR and the ligand can be readily identified by FACS.
  • the autocrine-based selection selects for functional interactions where antibody binding to the peptide on the CAR activates the system.
  • Lymph node biopsies from 3 patients with Follicular lymphoma were used to determine the nucleotide sequence of the BCRs from malignant cells.
  • the central part of the tumor biopsy was taken in order to reduce the abundance of BCR genes from non-malignant cells.
  • Total mRNA was used as a template in a reverse transcription reaction with subsequent PCR amplification of Ig V genes. Up to 95% percent of analyzed sequences were identical due to the clonal nature of lymphomas.
  • the selected Ig variable regions were cloned into the pComb3X vector in a scFv format (5).
  • the ScFv fused with constant domain of antibody (Fc) is linked via a flexible linker to a membrane-spanning domain of the platelet-derived growth factor receptor (PDGFR) such that the antibody molecules are integrated as dimers into the plasma membrane with their binding sites facing the solvent (5) ( FIGS. 5B and 5C ).
  • PDGFR platelet-derived growth factor receptor
  • FIG. 2A An autocrine-based reporter system for direct selection of ligands that are specific to the BCR on malignant cells ( FIG. 2A ) was used.
  • the method allows direct selection of a ligand that may be used for tumor targeting.
  • T cells infected with both the BCR and combinatorial cyclopeptide library containing 10 9 members were used as the reporter system.
  • Immortal Jurkat human T lymphocytes were modified to simultaneously express the lymphoma BCR and a randomized 7 amino acid cyclopeptide library.
  • the cyclopeptide library was fused with a chimeric antigen receptor containing signaling domains ( FIGS. 5A-5C ).
  • the signaling domains of the chimeric antigenic receptor trigger a T cell activation cascade.
  • Activated T-cells start to express CD69 (early T-cell activation antigen) (6) and thus may be easily detected utilizing specific fluorescent-labeled antibodies.
  • the capacity of the reporter construction was confirmed using a model system.
  • a c-Myc epitope on CAR and the variable domains of the anti-Myc antibody (9E10 clone) was used as a model membrane bounded BCR.
  • Jurkat cells expressing only membrane-bound anti-Myc antibody without co-expression of Myc-CAR showed no detectable activation. But, cells containing both membrane-bound anti-Myc antibody and Myc-CAR were activated FIG. 2B ).
  • T cells transduced with the FL1-CAR, FL2-CAR and FL3-CAR constructs demonstrated killing activity in vitro when incubated with the Raji lymphoma cell lines transduced with the isolated follicular lymphoma B cell receptors (FL-BCR).
  • FL-BCR isolated follicular lymphoma B cell receptors
  • lentiviral vectors coding for the FL1-CAR, FL2-CAR, FL3-CAR or CD19-CAR were used to transduce human CD8+ T cells.
  • Activated human CD8+ T-cells baring peptide-CAR lysed Raji cells expressing the corresponding BCRs from the lymphomas (Raji-FL1, Raji-FL2 and Raji-FL3), as measured by LDH release ( FIG. 3B ).
  • the specific cytotoxicity of the FL1-CAR, FL2-CAR and FL3-CAR cells was comparable to the best-studied CD19 CAR-T cell targeting CD19 antigen (FMC63-CAR).
  • cytotoxicity was estimated ex vivo of the FL1-CART against cells from the patient 1 initial biopsy. More than 60% of cells in biopsy sample are B-cells specific to the FL1 peptide ( FIG. 3C , bottom; panels). Cells from a control biopsy sample derived from another patient with follicular lymphoma (patient 4) did not demonstrate any significant staining by FL1 peptide.
  • the CTL assay showed that FL1-CAR-T specifically lysed cells from the biopsy sample, while Myc-CAR-T and Mock T cells did not have any anti-tumor lytic activity ( FIG. 3D ).
  • the efficacy of FL1-CART was tested in a relevant model of follicular lymphoma using immune-deficient NOD SCID (CB17-Prkdc scid /NcrCrl) mice engrafted with 5 ⁇ 10 6 Raji cells expressing the FL1-BCR (Raji-FL1) ( FIG. 4A ).
  • Lentiviral vectors coding for FL1-CAR, Myc-CAR or CD19-CAR were used to transduce CD3/CD28 bead-activated human CD8 + T cells resulting in a high efficiency of gene transfer ( FIG. 4B ).
  • CD8 + CAR-expressing T cells were correlated with expression of surface markers associated with effector phenotypes ( FIG. 4E ).
  • the population of FL1-CART in peripheral blood generally consisted of an effector memory subset, while spleen and bone marrow were expanded by a central memory subset of cells ( FIG. 4F ). These later cells are thought to be important for persistence and sustained anti-tumor activity.
  • T cells modified by these peptides fused with CAR efficiently eliminate tumor cells both, ex vivo and in vivo as efficiently as the well-known CD19-targeted CAR.
  • One advantage of this approach to antigen selection is that after the rounds of panning the selected peptide ligands are already in a construct where they are fused to the chimeric antigen receptor. This allows one to immediately generate therapeutic T lymphocytes modified by tumor-specific CAR.
  • the format reported here is the opposite of the usual CART protocol.
  • target is a surface peptide or protein of the tumor cell.
  • the inverse is used in that binding of the CAR-T is directed by the peptide and a target is an antibody.
  • the antibody molecule is part of a huge diversity system, the target universe is basically unlimited. This large target universe greatly simplifies the problem of selecting ligands that are highly specific and tightly binding.
  • the selected peptide sequences may be used to determine the proteins they are derived from and by inference the driving force for the malignant transformation.
  • the discovered peptide is homologous to a region of Myoferlin and identical to regions of surface proteins from Streptococcus mitis and Pneumocytis jirovecii ( FIGS. 8A-8E ).
  • the driving force for generation of lymphoid malignancies will be investigated as more antigens that bind to the BCR are unearthed.
  • the ability to use sequences other than CD19 as targets not only expands the choice in a therapeutic setting but also my help when the CD19 is absent or down regulated as may occur in many patients.
  • Lymphoma biopsy samples and patient mononuclear cell apheresis material were provided by N.N. Petrov Research Institute of Oncology (St. Russia) from a patient with advanced follicular lymphoma scheduled to receive high dose chemotherapy and ASCT.
  • CD34+ HSC were isolated from apheresis material using anti-human CD34 microbeads and MACS cell separation technique as per the manufacturer's protocol (Miltenyi Biotech). Cell purity following MACS separation was >98% as determined by flow cytometry following staining of the purified cells with anti-CD34-PE conjugated (Miltenyi). The remaining mononuclear cell fraction was used for isolation of CD8 T cells.
  • Both CD34+ cells and CD8 T cells were cryopreserved until use. Fresh and viable samples of lymphoma tissue obtained through biopsy were cut at 3-5 mm 3 pieces and implanted subcutaneously at multiple sites to four six week old female NOD SCID (CB17-Prkdc scid /NcrCrl) (Laboratory Animals at the Institute of Cytology and Genetics, SB RAS).
  • mice 5 weeks of age were acclimatized for at least a 7-day period and were myeloablated by sublethal whole body irradiation (325 rad) delivered by a Gammacell 40 Exactor (Best Theratronics).
  • 18 mice were injected with 0.25 ⁇ 10 6 purified CD34+ HSC cells per animal in a total volume of 200 mkl of phosphate-buffered saline (PBS) via the tail vein. All engrafted mice were housed under BL-2 conditions and provided with autoclaved and water supplemented with Baytril (enrofloxacin).
  • mice were bled via the mandibular route (cheek pouch) using a sterile lancet (Braintree Scientific). Approximately ⁇ 100 mkl of blood was collected each time in K 2 EDTA coated BD microtainer capillary blood collector tubes (Fisher Scientific).
  • the tubes were spun down at 500 ⁇ g for 5 minutes for separation of the plasma.
  • the cell pellet was treated with ACK lysis buffer to lyse RBC and washed extensively with MACS buffer containing BSA (Miltenyi) to enrich for peripheral blood mononuclear cells (PBMC).
  • BSA Miltenyi
  • PBMC Human PBMC, used as controls during flow cytometry analysis (FACS), was purified from leukapheresis blood collars, following standard Ficoll density gradient centrifugation techniques. Immunophenotyping was performed by staining the mononuclear cells with flurochrome conjugated antibodies specific for different human immune cell surface markers (e.g., CD45, CD3, CD19, CD4, CD8, etc.) followed by multi-colour flow cytometry using a LSRII Flow Cytometr (Becton Dickinson, N.J.). Antibodies were obtained from eBioscience, Biolegend or BD Biosciences. During FACS, cell gating was done on viable lymphoid cells based on the forward and side scatter profile and most analysis performed on cells within the lymphoid gate.
  • flurochrome conjugated antibodies specific for different human immune cell surface markers (e.g., CD45, CD3, CD19, CD4, CD8, etc.) followed by multi-colour flow cytometry using a LSRI
  • MSD 96-well High Bind Multi-Array plates were coated with 5 mkl of either anti-human IgM or anti-human IgG Fc (Bethyl Laboratories) at a concentration of 20 mkg/ml per well at 4° C. overnight. Plates were blocked with PBS/2% fetal bovine serum for 1 h followed by repeated washing with PBS/0.05% Tween-20.
  • Mouse plasma samples were tested at 1:50-1:100 dilutions for human IgG levels and 1:500-1:1000 dilutions for human IgM levels in a total volume of 20 ⁇ l for each sample added per well in duplicates. Following incubation and washing as described earlier, 20 ⁇ l goat anti-human Ig antibody with SULFO-Tag at a concentration of 2 ⁇ g/ml per well was used as the detection Ab and plates incubated for 1 h at room temperature. Plates were developed by adding the appropriate substrate and read on the MSD Sector Imager 2400 according to the manufacturer's protocol. Human IgM and IgG standards (Bethyl Labs) was used to obtain the standard curve and human of Ig levels computed using GraphPad Prism program version 5. The results are summarized in FIGS. 9-11 .
  • Identification of the BCR on the malignant B cell is specified in RU 2017134483.
  • Autocrine-based selection of a ligand for the BCR on the malignant cells is specified in RU 2017134483.
  • Lentiviral CAR T construct is specified in RU 2017134483.
  • Dynabeads CD8 Positive Isolation Kit (Life Technologies) was utilized for isolation of CD8 T cells from patient PBMCs fraction collected by apheresis.
  • Human CD8 T cells were activated with CD3/CD28 beads at a 1:1 ratio (Life Technologies) in a complete RPMI media containing 40 IU/ml recombinant IL-2 for 72 hours.
  • Activated T cells were re-suspended at concentration of 4 million cells per 3 ml of FL1-CART in lentiviral supernatant plus 1 ml of fresh RPMI media with 40 IU/ml IL-2 and cultured in 6-well plates. Plates were centrifuged at 1200 ⁇ g for 90 minutes at 32° C. and then incubated for 4 hours at 37° C. Second and third transductions were performed two more times.
  • VH and VL were cloned into the pFUSE antibody expression vectors (Invivogen) and produced utilizing FreeStyle 293 Expression System (Thermo Fisher Scientific). Protein was further purified and coupled to keyhole limpet hemocyanin using 0.1% glutaraldehyde as described by Levy (R. Levy. 1987 et al., Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived IgM and its molecular subunits. J Immunol. 139:2825.).
  • Human IgG Isotype Control antibody (Invitrogen, cat 12000C) was conjugated to keyhole limpet hemocyanin as used as the control vaccine. Mice were immunized using subcutaneous injections with 0.1 ml with an emulsion of equal parts Freund's complete adjuvant and KLH-IgG at 100 mkg/ml in PBS.
  • the combination of intravenous FL1-CART therapy and vaccination using the patient BCR vaccine results in synergistic suppression of tumor growth.
  • the combination of intravenous FL1-CART therapy with isotype control vaccine reduces efficacy of FL1-CART therapy.
  • MSD analysis of the terminal plasma samples were performed to measure antibody responses against the patient specific BCR and IgG Isotype Control
  • MSD analysis of plasma reactivity to the respective antigens were measured and compared. Data is represented as mean+/ ⁇ SEM.
  • the combination of intravenous FL1-CART therapy and vaccination using patient BCR vaccine results in the highest levels of anti BCR reactivity versus BCR vaccine alone.
  • Epidermal growth factor receptor variant III is the result of a novel tumor-specific gene rearrangement that produces a unique protein expressed in approximately 30% of gliomas, and certain other cancers including lung, breast and ovarian cancers.
  • EGFRvIII bypasses the need of ligand. This deletion spans exons 2-7, resulting in the introduction of a novel glycine residue at the fusion junction. While this mutant cannot bind ligands, it resides at the cell membrane and present a case of well-established personalized cancer model antigen harbouring a tumor specific mutation.
  • mice 5 weeks of age were acclimatized for at least a 7-day period and were myeloablated by sublethal whole body irradiation (325 rad) delivered by a Gammacell 40 Exactor (Best Theratronics).
  • 18 mice were injected with 0.25 ⁇ 10 6 purified CD34+ HSC cells per animal in a total volume of 200 mkl of phosphate-buffered saline (PBS) via the tail vein. All engrafted mice were housed under BL-2 conditions and provided with autoclaved and water supplemented with Baytril (enrofloxacin).
  • a EGFRvIII targeting 139-scFv-based CAR vector was assembled using scFv sequence from human anti-EGFRvIII antibody 131 to T-cell signalling domains from CD28-41BB-CD31 as described by Rosenberg (Steven A. Rosenberg et al., Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma, Hum Gene Ther.
  • DNA fragment coding for CD28-41BB-CD3 ⁇ was synthesized (GeneCust) and cloned into the pLV2 lentiviral vector (Clontech) under control of the EF1a promoter.
  • the arrangement of genes is in the order of: IL2-signal sequence, 139-scFv, GGGS linker; a CD28 trans-membrane and intracellular region; intracellular domains of the OX-40 and CD3zetta.
  • the lentiviruses were prepared by co-transfection of HEK293T cells with the pLV2-139-scFv-CD28-41BB-CD3zetta plasmid and the packaging plasmids (2 nd generation). Supernatants containing the virus were collected at 48 h post transfection. The titer of lentivirus preparations was determined using Lenti-X p24 ELISAs (Clontech).
  • CD8 Positive Isolation Kit (Life Technologies) was utilized for isolation of CD8 T cells from patient PBMCs fraction collected by apheresis.
  • Human CD8 T cells were activated with CD3/CD28 beads at a 1:1 ratio (Life Technologies) in a complete RPMI media containing 40 IU/ml recombinant IL-2 for 72 hours.
  • Activated T cells were re-suspended at concentration of 4 million cells per 3 ml of CD28-41BB-CD3-CAR in lentiviral supernatant plus 1 ml of fresh RPMI media with 40 IU/ml IL-2 and cultured in 6-well plates. Plates were centrifuged at 1200 ⁇ g for 90 minutes at 32° C. and then incubated for 4 hours at 37° C. Second and third transductions were performed two more times.
  • LEEKKGNYVVTDHC 14-amino acid peptide corresponding to the amino acid sequence at the fusion junction (LEEKKGNYVVTDHC) (SEQ ID NO: 30), was synthesized, purified, and coupled to keyhole limpet hemocyanin as described by Bigner (Monoclonal Antibodies against EGFRvIII are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas. Darell D. Bigner et al., Cancer Res. 1995 Jul. 15;55(14):3140-8.).
  • LEEKKGNYVVTDHC SEQ ID NO: 30
  • the data confirm the finding of substantial therapeutic synergy between CAR T adoptive immunotherapy and vaccination wherein both targets same personalized cancer antigen.
  • a phage-displayed cyclopeptide library panning may be performed for identification of the malignant BCR specific moiety.
  • phage-peptide libraries such as New England Biolabs Ph.D.-7 and Ph.D.-12 libraries may be utilized.
  • Ph.D.TM-C7C Phage Display Cyclopeptide Library Kit uses NNK coding moiety flanked by Cysteines shown in FIG. 19 .
  • modified NEB protocol for a malignant BCR specific peptides identification. It is recommended to perform negative-selection incubation during each round of panning.
  • Results of the panning are shown in the following tables.
  • Patent FL1 is as described in Example 1.
  • Table 3 shows ELISA results for the binding of amplified phages resulting from I-III rounds of panning against the BCR of patient FL1 with the BCR of patients FL1 and FL5 at the phage concentrations shown. Results are also shown in FIG. 20 .
  • the positive clones from Table 4 were amplified and sequenced. The sequence, location on Table 4, and OD are shown below in Table 6.
  • the peptide identified as binding the BCR of patient FL1 was also identified as a BCR ligand in Example 1 using the autocrine signaling method.
  • Primer FL1peptide FW (SEQ ID NO: 43) TCACGAATTCGGCTTGTATTCTTGATTTGCCGAAGTTTTGCGGTGGAGG TTCGGCTAGC Primer FL1peptide Rev (SEQ ID NO: 44) GCTCGCTAGCCGAACCTCCACCGCAAAACTTCGGCAAATCAAGAATACA
  • the PCR product was cloned into the pLV2-Fc-CAR vector at the EcoRI and NheI restriction sites.
  • inventive embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed.
  • inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein.
  • a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
  • the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
  • This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
  • “at least one of A and B” can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
US16/753,635 2017-10-04 2018-10-04 Articles and methods directed to personalized therapy of cancer Abandoned US20200271657A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
RU2017134483A RU2017134483A (ru) 2017-10-04 2017-10-04 Препараты и методы, предназначенные для персонализированного лечения рака
RU2017134483 2017-10-04
RU2018112009 2018-04-04
RU2018112009A RU2018112009A (ru) 2018-04-04 2018-04-04 Предметы и способы, предназначенные для персонализированного лечения рака
RU2018134321 2018-10-01
RU2018134321A RU2018134321A (ru) 2018-10-01 2018-10-01 Предметы и способы, предназначенные для персонализированного лечения рака
PCT/RU2018/000653 WO2019070161A2 (fr) 2017-10-04 2018-10-04 Articles et procédés destinés à la thérapie personnalisée du cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2018/000653 A-371-Of-International WO2019070161A2 (fr) 2017-10-04 2018-10-04 Articles et procédés destinés à la thérapie personnalisée du cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/983,673 Continuation US20200363420A1 (en) 2017-10-04 2020-08-03 Articles and methods directed to personalized therapy of cancer
US16/983,491 Continuation US11215618B2 (en) 2017-10-04 2020-08-03 Articles and methods directed to personalized therapy of cancer

Publications (1)

Publication Number Publication Date
US20200271657A1 true US20200271657A1 (en) 2020-08-27

Family

ID=64744919

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/753,635 Abandoned US20200271657A1 (en) 2017-10-04 2018-10-04 Articles and methods directed to personalized therapy of cancer
US16/983,673 Abandoned US20200363420A1 (en) 2017-10-04 2020-08-03 Articles and methods directed to personalized therapy of cancer
US16/983,491 Active US11215618B2 (en) 2017-10-04 2020-08-03 Articles and methods directed to personalized therapy of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/983,673 Abandoned US20200363420A1 (en) 2017-10-04 2020-08-03 Articles and methods directed to personalized therapy of cancer
US16/983,491 Active US11215618B2 (en) 2017-10-04 2020-08-03 Articles and methods directed to personalized therapy of cancer

Country Status (9)

Country Link
US (3) US20200271657A1 (fr)
EP (1) EP3692370A2 (fr)
JP (2) JP2020536115A (fr)
KR (1) KR20210027230A (fr)
CN (2) CN112020648A (fr)
AU (1) AU2018344859A1 (fr)
CA (1) CA3078460A1 (fr)
IL (1) IL273790B1 (fr)
WO (1) WO2019070161A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12111319B2 (en) * 2017-10-04 2024-10-08 Hesperix SA Articles and methods directed to personalized therapy of cancer
US20200271657A1 (en) 2017-10-04 2020-08-27 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
CN112327883B (zh) * 2020-11-27 2023-01-03 哈尔滨工程大学 基于扩张状态观测器的欠驱动水面船路径跟踪控制方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1186660A3 (fr) 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5112767A (en) 1988-03-04 1992-05-12 University Of Southern California Vectors with enhancer domains
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (fr) 1988-09-02 1997-04-02 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
EP0832980B1 (fr) 1989-01-23 2002-06-19 Chiron Corporation Thérapie recombinante des infections et désordres hyperprolifératifs
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1026253B2 (fr) 1989-03-21 2012-12-19 Vical Incorporated Expression de séquences polynucléotidiques exogènes chez un vertébré
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993010218A1 (fr) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (fr) 1992-06-08 1995-11-22 Univ California Procedes et compositions permettant de cibler des tissus specifiques.
WO1993025698A1 (fr) 1992-06-10 1993-12-23 The United States Government As Represented By The Particules vecteurs resistantes a l'inactivation par le serum humain
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2145641C (fr) 1992-12-03 2008-05-27 Richard J. Gregory Vecteurs pseudo-adenoviraux
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2115811A1 (fr) 1993-02-17 1994-08-18 Claus Krebber Methode de selection in vivo de proteines fixatrices de ligands
DK0695169T3 (da) 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0716148B1 (fr) 1993-09-15 2004-01-02 Chiron Corporation Vecteurs composés d'alphavirus recombinants
RU2162342C2 (ru) 1993-10-25 2001-01-27 Кэнджи Инк. Рекомбинантный аденовирусный вектор и способы его применения
RO116341B1 (ro) 1993-11-16 2001-01-30 Depotech Corp La Jolia Lipozom multivezicular si procedeu de obtinere a acestuia
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5627024A (en) 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
ATE239799T1 (de) 1995-09-07 2003-05-15 Novozymes As Nachweis der aktivität von enzymen für detergenzien durch phagen.
ATE496288T1 (de) 1995-10-11 2011-02-15 Luminex Corp Gleichzeitige mehrfachanalyse klinischer proben
SE506771C2 (sv) 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
EP0953052B1 (fr) 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Vecteurs retroviraux sans croisement
WO1998031700A1 (fr) 1997-01-21 1998-07-23 The General Hospital Corporation Selection de proteines a l'aide de fusions arn-proteine
WO2000053211A2 (fr) 1999-03-09 2000-09-14 University Of Southern California Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (fr) 2000-06-12 2001-12-20 Akkadix Corporation Matieres et procedes de lutte contre les nematodes
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
CA2462113C (fr) 2001-10-01 2013-01-29 Dyax Corp. Vecteurs d'affichage eukaryotes multichaine et leurs utilisations
US8148171B2 (en) 2001-10-09 2012-04-03 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
EP1556162A1 (fr) 2002-11-01 2005-07-27 McMaster University Microreseaux de proteines a plusieurs composants
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
CA2537055A1 (fr) 2003-08-22 2005-04-21 Medimmune, Inc. Humanisation d'anticorps
WO2008100791A1 (fr) 2007-02-16 2008-08-21 Rules-Based Medicine, Inc. Procédés et kits pour le diagnostic d'une drépanocytose
EP2890836B1 (fr) 2012-08-31 2019-07-17 The Scripps Research Institute Procédés liés à des modulateurs de cellules eucaryotes
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
EP3209626A4 (fr) 2014-10-20 2018-03-21 The Scripps Research Institute Procédés basés sur la proximité pour la sélection de partenaires de liaison
EA201790946A8 (ru) 2014-12-01 2018-10-31 Зе Скриппс Рисёрч Инститьют Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы
CN107847543A (zh) 2015-04-01 2018-03-27 斯克利普斯研究院 与gpcr激动剂多肽相关的方法和组合物
CN107708740A (zh) * 2015-06-10 2018-02-16 萨尔布吕肯大学 用于治疗b细胞恶性肿瘤的手段和方法
CA3018382A1 (fr) * 2016-03-29 2017-10-05 University Of Southern California Recepteurs antigeniques chimeriques ciblant le cancer
WO2017197081A2 (fr) 2016-05-13 2017-11-16 The Scripps Research Institute Variants peptidiques de venin bloquant kv1.3 et utilisations associées
US20200271657A1 (en) 2017-10-04 2020-08-27 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
RU2017134483A (ru) 2017-10-04 2019-04-08 Алексей Вячеславович Степанов Препараты и методы, предназначенные для персонализированного лечения рака

Also Published As

Publication number Publication date
US20210333282A9 (en) 2021-10-28
CN118497126A (zh) 2024-08-16
IL273790A (en) 2020-05-31
US20200363420A1 (en) 2020-11-19
US11215618B2 (en) 2022-01-04
CA3078460A1 (fr) 2019-04-11
WO2019070161A9 (fr) 2019-06-20
KR20210027230A (ko) 2021-03-10
JP2020536115A (ja) 2020-12-10
JP2024133625A (ja) 2024-10-02
EP3692370A2 (fr) 2020-08-12
AU2018344859A1 (en) 2020-04-30
CN112020648A (zh) 2020-12-01
US20200400676A1 (en) 2020-12-24
WO2019070161A2 (fr) 2019-04-11
IL273790B1 (en) 2024-10-01
WO2019070161A3 (fr) 2019-09-12

Similar Documents

Publication Publication Date Title
AU2019216689C1 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
RU2741120C2 (ru) Лечение рака с использованием химерного антигенного рецептора cll-1
ES2962651T3 (es) Composiciones y métodos para la inhibición de antígenos específicos de linaje
EP3298033B1 (fr) Compositions et usage medical de reprogrammation de tcr au moyen de protéines de fusion
TWI719942B (zh) 使用ｃｄ３３嵌合抗原受體治療癌症
AU2022231783A1 (en) Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
KR20220104217A (ko) Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
KR20210020932A (ko) Bcma 키메라 항원 수용체 및 이의 용도
KR20200089285A (ko) Bcma-표적화 키메라 항원 수용체, cd19-표적화 키메라 항원 수용체, 및 병용 요법
CN116082518A (zh) 一种结合bcma的嵌合抗原受体（car）及其应用
US20230074800A1 (en) Car-t cell therapies with enhanced efficacy
US11215618B2 (en) Articles and methods directed to personalized therapy of cancer
CN114230670A (zh) 靶向血液恶性肿瘤之嵌合抗原受体（car）、其组合物及使用方法
CN115058395A (zh) 嵌合抗原受体(car)、组合物及其使用方法
CN113661180A (zh) Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
CN110352197B (zh) 嵌合氯毒素受体
WO2021186397A1 (fr) Compositions de cellules car t gpc3 et leurs procédés de fabrication et d'utilisation
US12111319B2 (en) Articles and methods directed to personalized therapy of cancer
TW202304960A (zh) 靶向claudin-3之嵌合抗原受體及治療癌症之方法

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: THE SCRIPPS RESEARCH INSTITUTE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:XIE, JIA;REEL/FRAME:052524/0609

Effective date: 20181003

Owner name: HESPERIX SA, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STEPANOV, ALEXEY VYACHESLAVOVICH;GABIBOV, ALEXANDER GABIBOVICH;GENKIN, DMITRY DMITRIEVICH;AND OTHERS;SIGNING DATES FROM 20190513 TO 20190517;REEL/FRAME:052525/0016

Owner name: OPKO PHARMACEUTICALS, LLC, FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LERNER, RICHARD A;REEL/FRAME:052524/0952

Effective date: 20190212

Owner name: SHEMYAKIN-OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY, RUSSIAN ACADEMY OF SCIENCES, RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STEPANOV, ALEXEY VYACHESLAVOVICH;GABIBOV, ALEXANDER GABIBOVICH;BELOGUROV, ALEXEY ANATOLIEVICH;REEL/FRAME:052524/0813

Effective date: 20181128

Owner name: PJSC PHARMSYNTHEZ, RUSSIAN FEDERATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENKIN, DMITRY DMITRIEVICH;REEL/FRAME:052524/0887

Effective date: 20181120

Owner name: THE SCRIPPS RESEARCH INSTITUTE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OPKO PHARMACEUTICALS, LLC;REEL/FRAME:052524/0682

Effective date: 20190214

STCB Information on status: application discontinuation

Free format text: ABANDONED -- INCOMPLETE APPLICATION (PRE-EXAMINATION)